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Summary 
Metastatic melanoma is a severe disease with a high rate of lethality. It is known to be 
resistant to current therapies. Since melanoma is immunogenic the development of an 
immunotherapy can be a promising possibility to enhance an antitumor effect in vivo. 
Memory T cells (MTC) have abilities to respond quicker to antigens and to release a 
broader spectrum of cytokines than naïve T cells. The ret transgenic mouse melanoma 
model was used in this study since it resembles the pathological situation of human 
melanoma in contrast to transplantation models. It has been previously shown that the 
bone marrow (BM) is a major site for the persistence of tumor-specific MTC in cancer 
patients. In addition, melanoma-specific MTC were also found in the BM of ret 
transgenic mice without macroscopic tumors. Therefore, we isolated CD3+ cells from the 
BM of ret transgenic mice with and without tumors.  
Therefore, we isolated CD3+ T cells from the BM of ret transgenic mice with and 
without tumors. After a 40 h ex vivo stimulation of bone marrow-derived T cells with 
melanoma antigen-loaded DC, which were treated with anti-PD-L1 antibody overnight, 
T cells revealed a higher IFN-γ production and an increased T cell activation in vitro. 
Moreover, activated CD8+ T cells displayed mainly a central memory phenotype and an 
increased level of CD69 expression after 40 h of co-culture with DC.  
Labeled melanoma-specific, stimulated memory T cells from ret transgenic mice migrated 
to skin tumor lesions, metastatic lymph nodes (LN), BM and spleen after adoptive 
transfer into ret transgenic tumor-bearing mice. A similar migration pattern was 
detected using stimulated TRP-2 TCR transgenic effector T cells. Furthermore, migrated 
CD8+ T cells showed an increase in effector memory (TEM) and effector phenotype at day 
7 post injection and a decrease of central memory and naive CD8+ T cells within tumor 
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lesions, whereas at day 3, central memory, effector memory, naive and effector CD8+ T 
cells were equally distributed.  
To investigate the anti-tumor activity of melanoma-specific memory T cells in vivo we 
adoptively transferred MTC, which were prior activated with DC, into tumor-bearing 
mice by i.c. injections. Mice receiving memory T cells showed a significantly longer 
survival compared to the control group. Mice receiving the phosphodiesterase-5 inhibitor 
sildenafil and adoptive transfer of MTCs displayed a significantly higher survival rate 
than mice treated with sildenafil or PBS only.  
We suggest that an adoptive transfer of melanoma-specific memory T cells activated 
with antigen-loaded DC, which were pre-treated with anti-PD-L1 antibodies, can 
enhance an anti-tumor response and therapeutic efficacy in vivo. 
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Zusammenfassung 
Das maligne Melanom ist gekennzeichnet durch ausgeprägtes Metastisierungspotenzial 
und es besteht Resistenz gegenüber gängige Behandlungsmethoden wie Chemotherapie 
und Bestrahlung. Deshalb ist es von großer Wichtigkeit neue Behandlungsstrategien zu 
entwickeln. Da das Melanom sehr immunogen ist, dient die Entwicklung einer 
Immuntherapie als eine vielversprechende Option. Ein Werkzeug hierfür ist die 
Verwendung des Spontanmelanom-Tiermodells, welches hinsichtlich genetischer, 
histopathologischer und klinischer Situation, dem humanen Melanom sehr ähnlich ist. 
Dieses Mausmodell wurde auch für die vorliegende Arbeit herangezogen. Gedächtnis-T-
Zellen besitzen die Fähigkeit schnelleren auf ein Antigen zu antworten und sie 
sekretieren ein viel breiteres Cytokinspektrum als naive T-Zellen. Es wurde vor Kurzem 
gezeigt, dass das Knochenmark als der Hauptort für persistierende Tumor-spezifische 
Gedächtnis-T-Zellen in Krebspatienten ist. Außerdem wurden Melanom-spezifische 
Gedächtnis-T-Zellen im Knochenmark ret transgener Mäuse ohne makroskopische 
Tumore gefunden. Basierend darauf, haben wir für unsere Untersuchungen CD3+ T-
Zellen aus den Knochen ret transgener Mäuse mit und ohne Tumore isoliert. 
Nach einer 40-stündigen Kokultur frisch isolierter T-Zellen mit Melanom-Antigen 
geladenen Dendritischen Zellen, welcher über Nacht mit einem anti-PD-L1 Antikörper 
behandelt wurden, zeigten T–Zellen eine erhöhte IFN-γ-Produktion und somit eine 
verstärkte T-Zell-Aktivierung, wenn der anti-PD-L1 Antikörper eingesetzt wurde. 
Desweiteren zeigten stimulierte T-Zellen   eine erhöhte CD69 Expression und die Kultur 
stellte hauptsächlich den „central memory“ CD8+ T-Zell Phänotyp dar.  
Markierte Melanom-spezifische Gedächtnis-T-Zellen aus ret transgenen Mäusen 
migrierten in den Tumor, die metastasierten Lymphknoten, das Knochenmark und die 
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Milz nach einem Adoptiven Transfer. Ein ähnliches Migrationsverhalten zeigten TRP-2 
TCR transgene „effector“ T-Zellen. Zudem zeigten die migrierten Zellen an Tag 7 ein 
Ansteigen des „effector memory“ und „effector“ CD8+ T-Zell-Phänotyps, während die 
Menge an naiven und „central memory“ T-Zellen abnahm. An Tag 3 nach dem 
Adoptiven Transfer war das Verhältnis von effector memory, central memory, naive und 
effector T-Zellen fast gleich. 
Um die anti-Tumor Aktivität Melanom-spezifischer Gedächtnis-T-Zellen in vivo zu 
untersuchen, wurde 40 h nach Kokultur mit Tumor-Antigen beladenen DC, ein 
Adoptiver Transfer in Tumor-tragende ret transgene Mäuse durchgeführt. Mäuse, welche 
mit aktivierten Gedächtnis-T-Zellen behandelt wurden, zeigten eine signifikant höhere 
Überlebensrate im Vergleich zur Kontrollgruppe. In der Kombinationstherapie mit dem 
Phosphodiesterase-5 Inhibitor Sildenafil, zeigte die Kombinationsgruppe, Sildenafil und 
Adoptiver Transfer, ebenfalls eine höhere Überlebensrate als Gruppen, die nur mit 
Sildenafil oder PBS behandelt wurden. Im Überlebensversuch mit TRP-2 TCR 
transgenen T-Zellen konnte man nur die Tendenz einer höheren Überlebensrate sehen, 
verglichen mit der Kontrollgruppe. 
Eine effektive Melanom-Immuntherapie könnte auf einem adaptiven Transfer in vitro 
restimulierter Gedächtnis-T-Zellen aus dem Knochenmark von Melanompatienten, 
zusammen mit Melanom-Antigen beladenen DC in Kombination mit der Neutralisierung 
des Tumormikromilieus basieren. 
  
List of abbreviations  viii 
 
 
I List of abbreviations 
A 
AEC 3-amino-9-
ethylcarbazole 
Ag  antigen 
APC  allophycocyanin 
APCs  antigen-presenting cells 
 
B 
BM  bone marrow 
BSA  bovine serum albumin 
 
C 
CAR chimeric antigen 
receptor 
CCR  C-C chemokine receptor 
CD  cluster of differentiation 
ConA  concavalin A 
CPD cell proliferation dye 
eFluor® 670 
CTLs  cytotoxic lymphocytes 
CTLA-4 cytotoxic T lymphocyte 
antigen 4 
Cy  cyanin 
 
D 
DC  dendritic cells 
DKFZ Deutsches 
Krebsforschungszentru
m 
DNA  desoxyribonucleic acid 
dH2O  distilled water 
DMSO dimethylsulfoxide 
DTIC dimethyl triazeno-
imidazole carboxamide 
(dacarbazine)  
 
E 
EDTA ethylenediaminetetra-
acetic acid  
e.g.  for example 
ELISPOT enzyme-linked 
immunospot 
ERK extracellular-signal 
regulated kinase 
et al.  et alteri 
etc  et cetera 
 
F 
FACS fluorescence activated 
cell sorting 
FCS  fetal calf serum 
FDA Food and Drug 
Administration 
FITC flourescein-
isothiocyanat 
FMO  fluorescence minus one 
FoxP3 forkhead box P3 
FSC  forward scatter 
 
G 
GM-CSF granulocyte-
macrophage colony-
stimulating factor 
 
 
List of abbreviations  ix 
 
 
H 
HRP  horseradish peroxidase 
 
I 
i.e.  that is 
IL  interleukin 
IFN  interferon 
IU  international unit 
 
L 
LN  lymph nodes 
 
M  
MAPK MAP kinase mitogen-
activated protein kinase 
MHC major 
histocompatibility 
complex  
MT  metallothionein 
MTCs  memory T cells 
 
P 
PBS phosphate buffered 
saline 
PD-1  programmed death 1 
PD-L1 programmed death 1 
ligand 1 
PE  phycoerythrin 
PerCP peridinin-chlorophyll-
protein complex 
pH  potentia hydrogenii 
PI  propidium iodide 
PRRs pattern recognition 
receptors 
PTO  phosphorothioate 
 
R 
ret rearranged during 
transfection 
rm  recombinant murine 
ROS  reactive oxygen species 
RPE   R-phycoerythrin 
rpm  rounds per minute 
RPMI Roswell Park Memorial 
Institute medium 
RT  room temperature 
 
S 
SA  secretion assay 
SEB staphylococcal 
enterotoxin B 
SSC  side scatter 
 
T 
TA  tumor-antigen 
tb tumor-bearing ret 
transgenic 
TCM  central memory T cell 
TCR  T cell receptor 
TEM  effector memory T cell 
tg ret transgenic without 
tumor 
TILs tumor infiltrating 
lymphocytes 
Tim-3 T cell immunoglobulin 
mucin-3 
TL  tumor lysate 
TME tumor 
microenvironment 
TNF  tumor necrosis factor 
Tregs  regulatory T cells 
TRP-2 tyrosinase related 
protein 2 
TRP-2(180-188) TRP-2 derived peptide  
  (residues 180-188) 
 
U 
UV  ultraviolet 
List of figures  x 
 
 
 
II List of figures 
 
Fig.1: Signaling pathway triggered by Toll-like receptors. ................................................. 2 
Fig.2: Memory T cell differentiation. ............................................................................... 10 
Fig.3: Different melanoma types. ..................................................................................... 14 
Fig.4: Immunoinhibitoty pathways. ................................................................................. 18 
Fig.5: Immunostimulatory and immunosuppressive factors in the tumor 
microenvironment. ................................................................................................ 22 
Fig.6: Schematic drawing of the MHC Dextramer. .......................................................... 40 
Fig.7: Principle of ELISPOT. .......................................................................................... 41 
Fig.8: Experimental setup of T cell migration. ................................................................ 44 
Fig.9: Expression of DC markers at day 8. ...................................................................... 46 
Fig.10: ELISPOT. ............................................................................................................ 48 
Fig.11: IFN-γ secretion assay. .......................................................................................... 49 
Fig. 12: Phenotypical analysis of co-cultured T cells. ...................................................... 51 
Fig.13: TRP-2-specificity of CD8+ T cells. ....................................................................... 51 
Fig.14: CD3+ T cell purification....................................................................................... 52 
Fig.15: Phenotype analysis after co-culture. .................................................................... 53 
Fig.16: T cell migration after i.p. injections. .................................................................... 55 
Fig.17: T cell migration after i.c. injections. .................................................................... 56 
Fig.18: Absolute amount of CPD+ migrated cells. ........................................................... 57 
Fig.19: T cell subsets within CD8+ T cells. ...................................................................... 58 
Fig.20: Survival of tumor-bearing mice after adoptive transfer. ...................................... 59 
Fig.21: Migration of TRP-2-specific effector T cells. ....................................................... 61 
Fig.22: Absolute amount of migrated TRP-2 TCR effector cells. .................................... 62 
List of figures  xi 
 
 
Fig.23: CD8+ T cell subsets in the tumor. ....................................................................... 63 
Fig.24: Effect of immunotherapy with TRP-2 TCR transgenic T cells on 
melanoma development in ret transgenic mice. ................................................. 64 
 
List of tables  xii 
 
 
 
III List of tables 
Table.1: Murine memory T cell surface markers. ............................................................... 8 
Table 2: Antibodies for flow cytometry ........................................................................... 30 
Table 3: Antibodies used for ELISPOT ........................................................................... 30 
Table 4: Other antibodies ................................................................................................ 30 
Table 5: TRP-2 Dextramer and peptide .......................................................................... 30 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  1 
 
 
1  Introduction 
1.1  The immune system 
The immune system is a very complex network of cells, tissues and molecules. The main 
task of the immune system is to defend the body against foreign invaders. To operate 
properly, an immune system must detect a large spectrum of agents, from viruses to 
parasitic worms, and distinguish them from the organism's own healthy tissue. As a 
respond to the immune system which detects and neutralizes intruders, pathogens can 
quickly evolve and adapt in order to escape the immune system. Therefore, the immune 
system has developed different defense mechanisms to identify and neutralize pathogens. 
All mechanisms are based on detecting structural features of the invaders that mark 
them as distinct from host cells (Chaplin, 2006; Hoffmann et al., 1999; Janeway, 2001a). 
The immune system is made of two arms, one is the innate immune system, specific for 
infectious non-self, and another one is the adaptive immunity which is specific for all 
non-self-antigens (Janeway, 2001a). 
 
1.1.1 INNATE IMMUNITY 
The first defense in the innate immunity occurs through the epithelial barrier and the 
mucociliary clearance. The recognition of the innate immune system is based on 
germline-encoded receptors. It includes the recognition of conserved repeating patterns 
from microorganisms, e.g. lipopolysaccharide (LPS) of Gram-negative bacteria, 
lipoteichoic acid (LTA) of Gram-positive bacteria, mannose and glycans, bacterial CpG 
DNA or double-stranded viral RNA. These molecules called pathogen-associated 
molecular patterns (PAMPs) can be found in the cell walls of Gram-negative bacteria, in 
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viruses, fungi and Gram-positive bacteria (Janeway, 1989). Receptors that can recognize 
them are known as pattern recognition receptors (PRRs) and they do not recognize self-
structures of the host (Janeway, 2001b). There are different types of PRRs such as the 
macrophage mannose receptor, scavenger receptor or toll-like receptors (TLRs).  
One very important event triggered by the activation of the innate immune system is the 
expression of co-stimulatory molecules, like CD80 (B7.1) and CD86 (B7.2) on the surface 
of antigen presenting cells (APCs), e.g. on dendritic cells (DC). Furthermore, the 
phagocytized molecules are either processed in the immunoproteasom of APCs and are 
presented on the major histocompatibility complex class I (MHC I) or they are degraded 
in endosomes and are presented on MHC class II (MHC II) which can be recognized as a 
complex by T lymphocytes (Hardardottir et al., 1995).  
Hence, APCs link the innate immunity with the adaptive immune system by presenting 
antigens which, are recognized by the T cell receptor (TCR) of T lymphocytes. 
 
Fig.1: Signaling pathway triggered by Toll-like receptors. Various PAMPs recognized by cognate 
PRRs expressed on APCs induce the expression of CD80 and CD86 molecules, which signal the presence of 
pathogens and allow activation of lymphocytes specific for antigens derived from the pathogens. Depicted are 
LPS recognition by TLR-4, proteoglycan recognition by TLR-2, and the recognition of CpG DNA by TLR-9 
(Janeway, 2001b).  
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1.1.2 APCS 
As mentioned above, APCs represent a link between the innate and adaptive immune 
system. T and B lymphocytes are known to be the major effector cells of the immune 
system. They can eliminate infected cells, neutralize and remove toxic substances. APCs 
are able to attain microbial and other antigens and display them on their surface in a 
sense that leads to the activation of T lymphocytes of the adaptive immune system.  
It can be distinguished between professional and non-professional APCs. There are 
different types of professional APCs, e.g. DC, macrophages and B lymphocytes. These 
kinds of cells are very efficient in internalizing foreign proteins and processing them to 
display fragments of the antigen bound to MHC class I or II molecules. After facing a 
pathogen or cytokines, APCs get activated and migrate into the T cell areas of local 
lymph nodes. On their way there, they pass different stages of maturation which leads to 
the expression of co-stimulatory molecules and a stable expression of peptide:MHC 
complexes on their surface (Germain, 1994). The internalization of foreign antigens can 
occur through phagocytosis, receptor-mediated endocytosis or macropinocytosis . TCRs 
and the CD8 co-receptor of cytotoxic T cells (CTL) recognize peptides originating in the 
cytosol delivered to the cell surface and bound to the MHC class I whereas CD4+ T cells 
recognize peptides arising in vesicular system and attached to MHC class II (Goldberg et 
al., 2002; Hiltbold and Roche, 2002).  
Peptides that bind to MHC class I are usually derived from intracellular bacteria or 
viruses, which are then degraded by the immunoproteasome. They are then transported 
from the cytosol by proteins called transporters associated with antigen processing-1 and 
-2 (TAP-1 and TAP-2) to the endoplasmatic reticulum (ER) membrane. In the ER 
lumen, they bind to the MHC class I molecules, which then can be exported as a 
complex to the cell surface. These molecules are expressed on every nucleated cell of the 
body (Schubert et al., 2000; Uebel and Tampe, 1999; Vigneron et al., 2004). 
MHC class II molecules are only found on APCs. They bind peptides for their 
presentation to CD4 T lymphocytes. Peptides binding to MHC class II molecules are 
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derived from extracellular pathogens or from pathogens, which have invaded the cell to 
replicate in intracellular vesicles. Vesicles containing MHC class II molecules fuse with 
endosomes containing processed peptides. Subsequently, peptides bind to the molecules 
and are transported to the cell surface (Hiltbold and Roche, 2002). 
In addition to the peptide presentation on MHC class I and II, professional APCs 
express co-stimulatory molecules, like CD80 and CD86, which are important for proper 
activation of T cells.  
 
1.1.3  DC 
DC are by far the most important APCs. They were characterized in 1973 by Ralph 
Steinman and Zanvil Cohn (Steinman and Cohn, 1973) since then they have gained a 
solid interest from immunologists. DC arise from hematopoietic progenitors of the BM 
and circulate through the blood, non-lymphoid and lymphoid tissues (Inaba et al., 1992) 
. A large part of the DC is constituted by myeloid derived DC, which evolve from CD34+ 
myeloid progenitors compared to the lesser amount of CD14+ lymphoid progenitors 
which differentiate into plasmacytoid DC (pDC) (Banchereau et al., 2000). pDC are a 
rare circulating population, which can produce large amounts of type I interferons in 
response to viruses or host-derived nucleic acid-containing complexes that bind to TLR7 
and TLR9 in their compartment (Liu, 2005). Myeloid DC express TLR2 and TLR4 on 
their surface and bind to different bacteria derived products, producing high amounts of 
IL-12 (Leenen et al., 1998). 
Immature DC have a high endocytic and phagocytic capacity important for antigen 
uptake, though, the expression of MHC class II and co-stimulatory molecules is very low 
which leads to a low stimulation of T cells. DC can recognize PAMPs of microbial 
products via PRRs, e.g. mannose-like receptors and the TLR family. (Iwasaki and 
Medzhitov, 2004; Reis e Sousa et al., 1993). During their maturation state, upon 
pathogen recognition, DC release high amounts of proinflammatory and anti-viral 
cytokines such as IFN-α and IL-12, which lead to the recruitment and activation of 
innate immune cells at the site of inflammation (Blander and Medzhitov, 2006; Reis e 
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Sousa, 2004). As soon as DC are mature, they lose their endocytic and phagocytic 
receptors, the expression of MHC II and co-stimulatory molecules like CD80, CD86 and 
CD40 on their surface increases to a high level. DC also change their morphology and 
activate the antigen-processing machinery (Allan et al., 2006). To activate T 
lymphocytes, DC express CCR7 receptors which respond to homeostatic chemokines 
CCL19 and CCL21 and guide DC through afferent lymphatics into the T cell areas of 
local draining lymph nodes. Here, DC select and activate antigen-specific T cells and 
induce their differentiation into effector cells, initiating thereby primary immune 
response (Banchereau et al., 2000; Rescigno, 2001).  
Utilizing DC as a tool to treat cancer, various clinical trials have been conducted using 
DC transducted with viral vectors, DC loaded with proteins or peptides and DC loaded 
with tumor lysates (Engell-Noerregaard et al., 2009). 
 
1.1.4 ADAPTIVE IMMUNE SYSTEM 
The adaptive immunity is also known as a specific or acquired immune system. It is 
classified in the cellular immunity and humoral immunity. The cellular immunity 
consists of T cells with their antigen-specific TCRs recognizing short antigen fragments 
bound to the MHC molecules and provides a basis of self-nonself discrimination 
(Blattman and Greenberg, 2004). The humoral immunity consists of B lymphocytes that 
express antigen-specific receptors and bind antigenic determinants present on soluble 
proteins, carbohydrates, or nucleic acids.  
After the initiation of the primary immune response by pathogens, a couple of days are 
necessary for the clonal expansion and differentiation from naïve into effector T 
lymphocytes and antibody-secreting B lymphocytes. Afterwards, antigen-specific immune 
cells are able to eliminate the pathogens or infected cells and neutralize pathogen-derived 
products (Medzhitov and Janeway, 1999). After the infection removal, most effector cells 
undergo apoptosis but some cells build the immunological memory that ensures a rapid 
reinduction of Ag-specific antibody and effector T cells after subsequent encounter with 
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the same pathogen (Sallusto et al., 2004). Immunological memory provides a long lasting 
and often lifelong protection and in use as a tool for immunotherapy establishment 
against melanoma (Murali-Krishna et al., 1999; Umansky et al., 2008). 
 
1.2  T cells 
Cellular immunity is based on two major T cell subsets, CD4+ and CD8+ T cells, which 
work together to mediate an effective immune response. These cells originate from the 
hematopoietic precursors in the bone marrow and mature in the thymus into naïve T 
cells (Borowski et al., 2002; Shortman and Wu, 1996). Each T cell expresses TCRs for a 
specific antigen which is formed during T cell maturation through somatic 
recombination. Thus, large amounts of T cells with a broad spectrum of receptors 
specific for a variety of peptide:MHC complexes emerges (Zerrahn et al., 1997). During 
positive selection in the thymus, T cells specific for endogenous MHC molecules are 
selected. The subsequent negative selection is important to eliminate T cells in the 
thymus stroma which bind with their TCR to self-antigens (Sprent and Webb, 1995).  
 CD4+ T helper T cells are able to provide cytokine-mediated help to form the B cell-
mediated humoral response as well as to improve the durability and quality of the CD8+ 
T cell-mediated cytotoxic response. They can be further divided into type 1 and type 2 
helper T cells (Mosmann et al., 1997). Type 1 helper T cells produce IL-2 and IFN-γ 
after activation triggered by binding to the peptide:MHC II complex on APCs and 
facilitate in this way the CTL activity. This phenotype is considered to contribute to the 
anti-tumor immunity. Type 2 helper T cells promote humoral immune response by 
secreting IL-4, IL-5 and IL-6 (Trombetta and Mellman, 2005).  
CTLs are able to induce death in infected cells. After activation, which occurs after 
binding to the peptide:MHC I complex on APCs, CTLs release cytokines and enzymes, 
e.g. perforin and granzymes, to lyse diseased cellular targets. Most of effector cells die 
after overcoming the infection (Barry and Bleackley, 2002). However, a few cells survive 
and remain as memory T cells. Here, the activation of memory T cells upon encounter 
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with the same antigen occurs after a very short time compared to the primary immune 
response, where the activation takes several days (Huang et al., 2004). Memory T cells 
are capable of quick differentiation into effector cells and secretion of a broad spectrum 
of cytokines.  
The utilization of T cells for immune-mediated therapy of cancer has gained a deep 
interest of immunologist. Opportunities of therapeutic manipulation of T cells to 
maximize anti-tumor immunity exist in different stages of T cell maturation and 
activation, e.g. monoclonal antibodies (mAb) blocking CTLA-4 on APCs to inhibit the 
interaction with CD28 on T cells that has been recently approved for the treatment of 
metastatic melanoma (Lipson and Drake, 2011). CD80 and CD86 interact with CD28 to 
promote T cell activation, and CD80/CD86 interact with the counter-regulatory 
molecule CTLA-4 to dampen it by feedback regulation (Ostrand-Rosenberg et al., 2002). 
 
1.2.1 MEMORY T CELLS 
Developing an immune memory, which enables to react quickly to antigens upon the re-
exposure with a higher potency and efficacy, is a hallmark of the adoptive immunity. 
This is characterized by 1) the response of memory T cells in the presence of lower 
antigen concentration, 2) the rapid clonal proliferation upon antigen stimulation (Barber 
et al., 2003; Wherry et al., 2003), 3) the potential to release a broader spectrum of 
cytokines, 4) the expression of peripheral tissue homing receptors and 5) a rapid display 
of effector functions (Dutton et al., 1998; Tanel et al., 2009). Moreover, memory T cells 
undergo antigen-independent self-renewal stimulated by cytokines such as IL-2, IL-7, IL-
15 and IL-21 to maintain the memory T cell pool (Kieper et al., 2002; Luckey et al., 
2006; Schluns et al., 2000). Memory T cells maintain in the body many years after 
antigen exposure, even though the pathogen was eliminated (Combadiere et al., 2004). 
Memory T cells differ from naïve T cells in their expression of surface molecules like 
CD45RB (mouse), CD45RA (human), CD45RO (human), CD44 (mouse), CD62L and 
CCR7 (human/mouse) (Sallusto et al., 1999). 
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1.2.2 MEMORY T CELLS SUBSETS 
Mouse as well as human memory T cells can be subdivided into different subgroups 
based on the expression of various cell surface molecules, e.g. homing markers, 
chemokines and cytokines (Masopust et al., 2001; Sallusto et al., 2004; Sallusto et al., 
1999). As shown in Table.1, both CD4+ and CD8+ T cells can be divided into naïve (TN), 
central memory (TCM) and effector memory T cells (TEM).  Naïve T cells express high 
levels of homing markers L-selectin (CD62L) and CCR7, binding the chemokines CCL19 
and CCL21, which are required for cell extravasation through high endothelial venules 
(HEV) into the secondary lymphoid organs (Forster et al., 1999).   
Surface marker 
(mouse) 
Naïve 
T cells 
Central memory 
T cells 
Effector memory 
 T cells 
CD45RB (CD4+) high low low 
CD44 (CD4+/CD8+) low high high 
CD62L (CD4+/CD8+) high high low 
CCR7 (CD4+/CD8+) high high low 
Table.1: Murine memory T cell surface markers. 
 
Murine central memory T cells do not differ much from naïve T cells regarding their 
phenotype except the expression of CD45RB. TCM reside in the lymph nodes, tonsils and 
the bone marrow (Campbell et al., 2001; Feuerer et al., 2001b; Sallusto et al., 1999). 
Upon exposure to antigens, long-lived TCM can rapidly differentiate into cells equipped 
with effector functions; they are more sensitive to antigenic stimulation and less 
dependent on costimulation (Sallusto et al., 2004; Sallusto et al., 1999). Furthermore, 
TCM have the ability of self-renewal and secrete high amounts of IL-2, which is necessary 
for the proliferation and differentiation of TN to become effector T cells. Compared to 
short-lived TEM, TCM have been shown to mediate a protective immunity because of their 
long-term persistence. This feature designates them as “stem cells” of the adoptive 
immune response (Bouneaud et al., 2005; Klebanoff et al., 2005; Zaph et al., 2004). 
Circulating CD4+ and CD8+ effector T cells are found in the peripheral blood, spleen and 
non-lymphoid tissue where they can respond quickly to foreign antigens by the 
production of effector molecules such as IFN-γ, IL-4 and IL-5 (Sallusto et al., 1999). In 
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addition, CD8+ TEM produce large amounts of perforin. In contrast to TCM, effector 
memory T cells do not express CCR7 and CD62L (Sallusto et al., 1999). However, the 
display characteristic sets of chemokines and adhesion molecules for homing into 
inflamed tissue. In addition, TEM respond with a higher potency to antigens than TCM 
(Sallusto et al., 2004). 
 
1.2.3 MODELS OF MEMORY T CELL DIFFERENTIATION 
Currently, there are three different models of memory T cell differentiation described in 
the literature (Fearon et al., 2006; Ganusov, 2007; Kalia et al., 2006; Lefrancois and 
Marzo, 2006). 
The first model is called stem cell-associated differentiation (SCAD). During the 
expansion phase of the immune response, terminally differentiated effector T cells are 
produced by sustained self-renewal of memory T lymphocytes. After antigen clearance, 
which is also known as the contraction phase, effector T cells undergo apoptosis and only 
a small amount of memory T cells remains in the system (Ahmed and Gray, 1996; 
Fearon et al., 2006; Wodarz et al., 2000) 
In the linear differentiation (LD) model, during the expansion phase activated T 
lymphocytes with an effector phenotype proliferate and die in the contraction phase after 
the antigen elimination and a few cells differentiate into long-lived memory T cells 
(Ahmed and Gray, 1996; Antia et al., 2005; Kaech et al., 2002; Lefrancois and Marzo, 
2006). 
The last model is called progressive differentiation (PD). Here, proliferating T cells 
progress through different stages of differentiation during the expansion phase. Cells 
receiving a weak signal will differentiate into memory T cells, those receiving a strong 
signal will transform into effector T lymphocytes (Fearon et al., 2006; Fearon et al., 
2001; Lefrancois and Marzo, 2006).  
However, there are some variations of these models. In the PD model three distinct 
stimulation patterns according to signal strength through antigens are described 
(Lanzavecchia and Sallusto, 2005).  Thus, the circulation of a low number of antigens in 
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the system leads to an incomplete activation of T lymphocytes through low stimulation. 
These T cells undergo apoptosis and the differentiation into memory T cells does not 
occur. In contrast, a circulation of high amounts of foreign antigen leads to an enhanced 
stimulation of T cells by the recruitment of additional APCs with upregulated MHC 
molecules on their surface and removal of the antigens. During this activation, some 
naïve T cells stop their transformation into effector cells and undergo differentiation into 
either TCM or TEM depending on the intensity of the antigen signal. TCM maintain in the 
body for a long time whereas TEM undergo apoptosis if they are not exposed to the same 
antigen. In case of constitutive strong antigen stimulation, naive T cells differentiate 
only into effector T cells Fig.2.   
 
 
Fig.2: Memory T cell differentiation. A model based on strength and quality of stimulatory signals. 
After T cell activation and during differentiation into memory T cells lose naïve properties and acquire 
effector properties. After elimination of the antigen, a few T cells remain as memory T cells (Sallusto and 
Lanzavecchia, 2011). 
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1.2.4 CD8+ MEMORY STEM CELLS 
Conventionally, memory T cells are divided into two subtypes based on their homing 
molecules CD62L and CCR7. However, a new subset of mouse memory T cells with stem 
cell like properties has been recently described (Gattinoni et al., 2009; Zhang et al., 
2005). These self-renewal T cells, so called memory stem T cells (TSCM), have a 
phenotype similar to naive T cells (CD44low and CD62Lhigh). Moreover, TSCM were found 
to express the stem cell antigen (Sca)-1 and high levels of the antiapoptotic molecule B 
cell lymphoma- 2 (Bcl-2), the β-chain of IL-2 and IL-15 receptor (IL-2Rβ), and the 
chemokine (C-X- C motif) receptor CXCR3 (Gattinoni et al., 2009). This memory 
subtype displayed an enhanced self-renewal capacity and the multipotency to generate 
all memory and effector T cell subsets in vitro (Gattinoni et al., 2009; Zhang et al., 
2005). Recently, TSCM were also found within a CD45RO−, CCR7+, CD45RA+, CD62L+, 
CD27+, CD28+ and IL-7Ra+ T cell compartment characteristic for naive T cells. 
Furthermore, they expressed high levels of CD95, IL-2Rβ, CXCR3 and LFA-1 and 
displayed various characteristics of memory T cells (Gattinoni et al., 2011).  
These recently identified memory T cells with stem cell properties have major 
implications for the design of new vaccination strategies and adoptive immunotherapy. 
 
1.2.5 BONE MARROW AS A NICHE FOR MEMORY T CELLS 
It has been demonstrated that the persistence of memory plasma cells occurs in the bone 
marrow in so-called survival niches. Therefore, the question was addressed whether T 
cells can also reside in the BM (Manz et al., 1997; Radbruch et al., 2006; Tokoyoda et 
al., 2009a). Recent studies have shown that both CD4+ and CD8+ T cells persist in the 
bone marrow stroma niches which serve as a reservoir for memory T cells (Beckhove et 
al., 2004; Duffy et al., 2012; Feuerer et al., 2001a; Feuerer et al., 2004; Feuerer et al., 
2001b; Mazo et al., 2005; Tokoyoda et al., 2009b). An essential role of IL-7 for memory 
CD4+ T cells and IL-15 for memory CD8+ T cells has been demonstrated (Snell et al., 
2012; Surh and Sprent, 2008). In the BM, CD4+ T helper memory cells persist in close 
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contact with VCAM-1+ stroma cells, which produce IL-7 to maintain these T 
lymphocytes (Tokoyoda et al., 2009b).   
The recruitment of memory T cells from the peripheral blood to the bone marrow follows 
by different mechanisms including the interaction of very late activation antigen (VLA)-
4 expressed on memory T cells and the vascular cell adhesion molecule (VCAM)-1, 
which is constitutively expressed in the bone marrow (Mazo et al., 2005). The binding of 
mucosal addressin cell adhesion molecule (MAdCAM)-1 to α4β7 integrin molecules, which 
is upregulated on memory T cells, is another mechanism of T cell recruitment into the 
bone marrow (Berlin et al., 1993; Erle et al., 1994; Mazo et al., 2005). 
 
1.2.6 TUMOR-SPECIFIC MEMORY T CELLS 
Tumor antigen specific memory T cells have been found close to dormant tumor cells in 
the bone marrow of mice previously vaccinated with tumor cells. It has been described 
that these memory T cells provide protection against further tumor challenge (Khazaie 
et al., 1994; Muller et al., 1998).  
Patients with breast cancer harbored tumor antigen-specific memory T cells in their 
bone marrow, which could be reactivated ex vivo with previously generated DC pulsed 
with the tumor lysate. After stimulation, they produced IFN-γ and attained cytotoxic 
activity against tumor antigens in vitro and in vivo (Beckhove et al., 2004; Feuerer et 
al., 2001b). The BM is considered to be the site of persistence for tumor specific memory 
T cell and low amounts of dormant tumor cells which are kept under control by the host 
immune control (Feuerer et al., 2001a). Tumor specific memory T cells were not only 
found in the BM of breast cancer patients but also in patients with pancreatic cancer 
and melanoma (Beckhove et al., 2004; Feuerer et al., 2001a; Muller-Berghaus et al., 
2006; Schmitz-Winnenthal et al., 2005). 
Utilizing the ret transgenic mouse melanoma model, it has been demonstrated that the 
bone marrow of mice with primary skin tumors contained high numbers of melanoma 
antigen-specific CD8+ T cells, with mainly effector memory phenotype (Umansky et al., 
2008). Furthermore, melanoma specific CD8+ effector memory T cells were detected in 
mice with disseminated melanoma cells in the LN and the BM but without macroscopic 
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tumors and no further tumor progression (Umansky et al., 2008).  Since tumor specific 
memory T cells from the BM of ret transgenic mice could be reactivated ex vivo, they 
were used for adoptive transfer in tumor-bearing mice (Umansky et al., 2008). 
Reactivated memory T cells from breast cancer patients were reported to recognize and 
reject xenotransplanted autologous tumors (Beckhove et al., 2004). 
 
1.3  Melanoma 
Malignant melanoma is an aggressive malignancy of transformed melanocytes. It is 
known to be resistant to standard therapy, i.e. chemo- and radiotherapy (Finn et al., 
2012). It is the most rapidly increasing malignancy in Western population in terms of 
incidence and is directly related to improving life standards such as travelling to sea 
resorts and getting tanned (Sapoznik et al., 2012). Although only approximately 5% of 
skin cancers account for melanoma, it is responsible for most skin cancer related deaths 
(Kanavy and Gerstenblith, 2011). Risk factors for melanoma development are solar UV 
radiation, fair skin, dysplastic nevi syndrome, and a family history of melanoma 
(Garibyan and Fisher, 2010; Ilkovitch and Lopez, 2008; Whiteman et al., 2006). 
Melanoma is more common in Caucasians than in African or Asian people. It is affecting 
generally young and middle-aged people, unlike other solid tumors and it is the most 
common malignancy in women aged 25-29 years (Brewer et al., 2011).     
Most commonly melanoma arises from the malignant transformation of melanin-
producing melanocytes in the skin, rarely in noncutaneous melanocytes such as the 
retina and uvea of the eyes, respiratory, gastrointestinal, and genitourinary mucosal 
surfaces, or the meninges (Tsao et al., 2012). Clinicians have traditionally divided the 
disease into different subgroups based on the TNM classification of malignant tumors. 
Stage I melanoma is described as an invasive melanoma where the tumor cell spread in 
situ. If the tumor reaches the size of 1.5 mm and more, it can be assigned to stage II, 
which is high risk melanoma with a 5-year survival rate of 45-79%. In stage III, the 
tumor begins to metastasize into regional lymph nodes and the skin. Stage IV has a 5-
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year survival rate of 7-19% and the tumor cells form distant metastases by spreading 
through the peripheral blood and lymphatic system into the brain, lung, liver skin and 
the bone marrow (Balch, 2002). In general, patients with thin lesions (>0.75 mm) have a 
5-year survival rate of greater than 99%, whereas patients with lesions >4 mm showed a 
5-year survival rate of less than 50% (Balch et al., 2003). 
According to the progression and invasion of melanoma, four subtypes can be described: 
superficial spreading melanoma, lentigo maligna melanoma, acral lentiginous melanoma, 
and nodular types (Reed and Martin, 1997). 
 
 
Fig.3: Different melanoma types.  (A) Patient with various melanoma lesions. (B) Superficial spreading 
and (C). nodular melanoma. (D) Acral lentiginous melanoma and (E) ocular melanoma. Tsao, H et al., 
Genes & Dev. 2012 
 
1.3.1 STANDARD THERAPIES OF MALIGNANT MELANOMA 
Surgical excision of the tumor with adequate margins and assessment for the presence of 
detectable metastatic disease along with short- and long-term follow-up belongs to the 
common standard procedure. However, surgery can be beneficial only for localized 
(primary) melanoma (Landthaler et al., 1989). 
Diverse chemotherapeutic agents have been used for treatment against melanoma but 
without a significant increase in the overall survival of patients (Bajetta et al., 2002). 
For instance, dacarbazine and temozolamide are used as a single therapy or in 
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combination as a polychemotherapy. Systemic therapy as a single-agent chemotherapy 
has not been successful until now. In contrast, polychemotherapy has increased the 
response rate but not the survival rate (Serrone et al., 2000). 
Patients with non-resectable distant metastases or with regionally and advanced 
melanoma are treated with radiotherapy. Although it is proven to be ineffective it is still 
commonly used after surgical resection to treat left tumor tissue (Mendenhall et al., 
2008). 
As adjuvant therapy interferon-α (IFN-α) is used after surgical removal since it has been 
shown an improvement in disease-free survival when applied in a high-dose manner 
(Kirkwood et al., 1996). IFN-α has an anti-proliferative effect on tumor cells by the 
downregulation of oncogenes and the induction of tumor suppressor genes. Therefore, it 
is associated with an enhancement of tumor immunogenicity through the upregulation of 
MHC class I on tumor cells (Bracci et al., 2007; Fang et al., 2008).  Therapy with IFN-α 
can increase the overall survival up to 15% (Mohr et al., 2003). 
 
1.3.2 MELANOMA IMMUNOTHERAPY  
Melanoma that is known as an immunogenic cancer has been considered as a prime 
target for immunotherapeutic approaches. Therefore, various immunological therapy 
strategies have been used in clinical trials as a promising treatment possibility compared 
to conventional therapies (Ortenberg et al., 2012). Ongoing efforts are made to find 
effective treatments of metastatic melanoma based on the immune system modulation 
(Sapoznik et al., 2012). Melanoma cells induce both innate and adaptive immune 
responses. Furthermore, immune cells are migrating to and infiltrate melanoma lesions 
(Thompson et al., 2010). Nevertheless, clinical studies are not very successful probably 
due insufficient immune cell number, their low cytotoxic potential and the inhibitory 
tumor microenvironment (Anichini et al., 2004; Harlin et al., 2006; Rosenberg et al., 
2005; Yuan et al., 2010). In the past 25 years, immunological research has led to the 
improvement of our knowledge about molecular mechanisms of the immune response. 
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Moreover, this better understanding has allowed the development of new methods to 
induce and manipulate the anti-tumor immune response ex vivo and in vivo (Lizee et al., 
2013). Recent studies have demonstrated that the regression of metastases after 
immunotherapy was linked to the activation of genes responsible for antigen presentation 
and interferon-mediated tumor rejection (Carretero et al., 2012). Several systemic 
treatment approaches include the administration of immune-stimulating cytokines, 
immunization with tumor cells or molecules, adoptive transfer of T cells, blocking 
antibodies against inhibitory molecules and inhibitors of mutated kinases (Klein et al., 
2011; Rosenberg et al., 2008; Shepherd et al., 2010; Weber, 2010).  
 
1.3.3 CYTOKINES 
Cytokines are small signaling proteins that are secreted by various immune cells. These 
signaling molecules function as regulators and immune-modulating agents. IL-2 is 
produced by T cells and enables the growth and expansion of T cells, expressing IL-2 
receptors on their surface (Morgan et al., 1976). In 1992, IL-2 was approved as the first 
immunotherapy for the treatment of metastatic renal cancer and in 1998 for the 
treatment of advanced melanoma (Rosenberg, 2012). Treatment with high-dose IL-2 can 
result in a complete regression, around 5-10% of patients, and additionally 10% in partial 
regression (Atkins et al., 1999; Rosenberg et al., 1998; Schwartzentruber et al., 2011; 
Smith et al., 2008). Furthermore, around 70% of complete responders to IL-2 therapy do 
not relapse which means that they are probably cured (Rosenberg et al., 1988).  
Other cytokines such as IL-21 were also studied in early-phase clinical trials. This 
cytokine can activate cytotoxic T cells promoting potent anti-tumor response in pre-
clinical studies and patients (Frederiksen et al., 2008; Hashmi and Van Veldhuizen, 2010; 
Rasmussen et al., 2010).  
Other cytokines involved in the activation (such as IL-7 and IL-15) have been 
investigated for a possible clinical application (Klebanoff et al., 2011b). Some 
immunotherapies aim the differentiation of CD8+ T cells at the tumor site toward 
effector and memory phenotypes since it is believed that these cells can elicit the most 
efficient anti-tumor response. In this respect, IL-7 and IL-15 used alone or in 
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combination may promote the maturation of anti-tumor CD8+ T cells and induce the 
regression of melanoma metastases (Le et al., 2009).  
 
1.3.4  CANCER VACCINES 
Another approach to elicit potent anti-tumor immune responses without side effects is 
the immunization with whole tumor cells, tumor specific peptides, recombinant viruses, 
DC, and naked DNA combined with different adjuvants (Allison, 1999; Banchereau and 
Palucka, 2005; Gorelik and Flavell, 2001; McGilvray et al., 2009; Nestle et al., 1998; 
Zaks and Rosenberg, 1998). The aim is to stimulate innate and adaptive immunity to 
recognize and eliminate tumor cells. Although therapeutic cancer vaccines showed an 
impressive anti-tumor activity in numerous animal models, their clinical benefit in cancer 
patients leaves much to be desired. Multiple clinical trials have achieved only low overall 
survival with rare complete responders (Klebanoff et al., 2011a; Rosenberg et al., 2004).   
 
1.3.5 ANTIBODIES 
Therapeutic antibodies have an advantage to circulate in the peripheral blood and lymph 
system where they can bind to targets. Monoclonal antibodies can be subdivided into 
either inhibitory or activating antibodies against co-inhibitory or co-stimulatory 
molecules respectively. Various approaches have been used in recent clinical trials 
(Ascierto et al., 2010; Robert et al., 2011; Sznol, 2010; Vonderheide et al., 2007).  
The lack of co-stimulation leads to peripheral T cell tolerance with no immune response 
or cell death through apoptosis (Croft, 2009). Pre-clinical studies in animal models have 
shown that sustaining co-stimulatory signaling will enhance T cell reactivity against 
tumor antigens (Croft, 2009). This facilitates an induction of cytotoxic CD8+ T cell 
response, leading to the tumor elimination by cell death (Croft, 2009). Some monoclonal 
antibodies utilized in the clinical trials are mentioned below.  
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Fig.4: Immunoinhibitoty pathways. Modified from Freeman et al. 2012 (Freeman and Sharpe, 2012).  
Ipilimumab, a monoclonal antibody, has been approved in March 2011 as an antibody-
based immune therapy for late-stage metastatic melanoma. This antibody increases the 
anti-tumor immunity by inhibiting CTLA-4, which acts as a negative regulator in the 
immune response (Korman et al., 2006). CTLA-4 is a homologue of T cell costimulatory 
CD28 but with higher binding affinity to its ligand (e.g. CD86). Once CTLA-4 is 
upregulated on the surface of activated cytotoxic T lymphocytes, it leads to cell cycle 
arrest and inhibition of proliferation of these cells, and as a consequence causes immune 
evasion (Korman et al., 2006; Peggs et al., 2006). In clinical trials, the treatment with 
ipilimumab of patients with inoperable stage III and IV melanoma achieved response 
rates range from 5-15%, with durable responses (Thumar and Kluger, 2010). Moreover, 
combination studies, including ipilimumab, to attain higher response rates in melanoma 
patients are in progress (Sondak et al., 2011).  
Another antagonistic antibody, blocking the negative T cell checkpoint, is directed 
against programmed death cell death (PD)-1 (MDX-1106; BMS-936558). PD-1 is 
expressed mainly on activated T cells and APCs (Weber, 2010). Its ligands are PD-L1 
(B7-H1) and PD-L2 (B7-H2). PD-L1 is expressed on macrophages, DC, B cells and T 
cells (Keir et al., 2008; Weber, 2010). High level of PD-L1 expression was also found on 
multiple tumor cells including melanoma (Dong et al., 2002; Kronig et al., 2012). It is 
believed that melanoma cells can induce durable PD-1 signaling which leads to T cell 
dysfunction and T cell exhaustion (Kronig et al., 2012). Therefore, since PD-1 is 
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expressed on tumors and stroma cells, PD-1 blockade might restore immune cell 
functions and induce anti-tumor response. Pre-clinical studies on PD-1 deficient mice 
showed an increased T cell response and cytokine production, leading thereby to the 
inhibition of the hematogenous spread of B16 melanoma cells (Iwai et al., 2002). The 
blockade of PD-L1 could enhance therapeutic efficiency of the combined immunotherapy 
in mice with B16 melanoma (Pilon-Thomas et al., 2010). Based on these findings, early 
phase clinical trials were initiated with anti-PD-1 antibodies as a single agent. Objective 
tumor response could be observed in 37.5% of patients (Brahmer et al., 2010). 
Furthermore, preliminary data suggest a relationship between PD-L1 expression on 
tumor cells and clinical response since patients with PD-L1-negative tumors had no 
objective response (Topalian et al., 2012).   
The combination of MDX-1106 with ipilimumab in patients with stage III or IV 
melanoma has been initiated in a phase I clinical trial (Davar et al., 2013).  
 
1.3.6  ADOPTIVE CELL THERAPY 
Based on the fact that host’s immune system is capable of producing anti-tumor 
response, various attempts have been performed to evoke an effective immune-mediated 
elimination of the tumor (Wu et al., 2012). As a highly promising approach, adoptive 
transfer of tumor-reactive autologous T cells into cancer patients is currently under 
intense investigation (Shapira-Frommer and Schachter, 2012). This strategy utilizes ex 
vivo cultured autologous T lymphocytes with specificity for tumor antigens. For an 
efficient treatment, these lymphocytes need to have the ability for the homing to tumor 
sites and the potential to destroy tumor cells in vivo (Shapira-Frommer and Schachter, 
2012; Zito and Kluger, 2012).  
 
Adoptive therapy of tumor infiltrating lymphocytes 
Since Steven Rosenberg first demonstrated that T lymphocytes infiltrated in melanoma 
metastasis could be grown in presence of IL-2 and are capable to recognize melanoma 
cells, adoptive cell therapy (ACT) protocols have developed (Dudley et al., 2008). In 
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1998, it was demonstrated that these autologous tumor infiltrating lymphocytes (TILs) 
have the ability to mediate tumor regression (Rosenberg et al., 1988). However, the 
durability rates were very low or absent. Therefore, lymphodepletion regimens were 
introduced prior to adoptive transfer. Lymphodepletion was performed to eliminate 
immune regulatory cells, to reduce the competition for growth factors and also to achieve 
an increase in serum concentrations of IL-7 and IL-15, which promote T cell growth 
(Dudley et al., 2008). 
After using cyclophosphamide to deplete immune suppressor cells and adding a high dose 
IL-2 administration to the adoptive transfer, an objective response of 34% among 86 
melanoma patients was detected (Rosenberg et al., 1994). Among different 
lymphodepletion protocols, such as fludarabine, cyclophosphamide and combination of 
both, the total body irradiation (TBI) was the most effective in maintaining transferred 
polyclonal TIL populations and expansion of cytotoxic CD8+ T cells in the blood 
circulation in vivo (Bernatchez et al., 2012; Dudley et al., 2008).  Lymphodepletion prior 
to adoptive transfer of TILs in combination with high dose bolus IL-2 has been shown to 
lead to around 50% of clinical response rates in patients with metastatic melanoma in 
nonrandomized phase II clinical trials (Dudley et al., 2005; Laurent et al., 2010). Those 
results remain to be validated in phase III clinical trials, although they are promising. 
 
1.3.7 TARGETED THERAPY 
Another therapy approach is targeting signaling pathway leading to the tumor 
progression (Inamdar et al., 2010). Several such drugs including BRAF and MEK 
inhibitors are now under evaluation (Spagnolo and Queirolo, 2012). Promising results 
have been recently achieved in phase I and II trials. A BRAF-inhibitor Vemurafenib has 
been approved in August 2011 for the treatment of patients with unresectable or 
metastatic melanoma with BRAF V600E mutation (Bernatchez et al., 2012; Ribas et al., 
2012). Phase I and II trial that combined a selective BRAF inhibitor and a selective 
MAPK kinase (MEK) inhibitor, showed a significant improvement of progressive-free 
survival in patients with metastatic melanoma (Flaherty et al., 2012). In addition, the 
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treatment with BRAF inhibitors has been shown to increase T cell infiltration of 
melanoma lesions (Boni et al., 2010; Comin-Anduix et al., 2010; Wilmott et al., 2012). 
In summary, tremendous efforts have been made for the development of new therapeutic 
strategies of metastatic melanoma. Multiple treatment options show promising results. 
However, to attain an efficient immune response against the tumor, a combination of 
different approaches, including adoptive immunotherapy seem to be the most auspicious 
way to go. 
 
1.3.8 TUMOR-INDUCED IMMUNOSUPPRESSION 
Although multiple therapeutic approaches show promising effects on the anti-tumor 
reactivity of T cells; such T cells activation does not always correlate in clinical trials 
with the therapeutic benefit. The immunosuppressive tumor microenvironment (TME) 
might play a role in the failure of these treatment approaches (Wu et al., 2012). Tumors 
have developed mechanisms to create an immunosuppressive network which can 
negatively influence immunotherapy. Although T cells are capable of infiltrating tumors, 
they fail to eliminate tumor cells due to their defected lytic machinery or the lack of 
active attack (Hanahan and Weinberg, 2011). This might be due to the presence of co-
inhibitory molecules or the downregulation of tumor specific antigens or MHC molecules 
on tumor cells (Vesely et al., 2011).  Since the downregulation of MHC class I favors 
tumor recognition by natural killer (NK) cells, tumor cells adjust their MHC I expression 
to minimize the recognition by either NK or T cells (Vivier et al., 2012). Furthermore, 
effector T cells are not capable to function properly due to the inhibition by 
CD4+CD25high, FoxP3+ regulatory T cells (Tregs), CD19+ CD25high regulatory B cells, IL-
13 producing NKT cells in the TME (Jacobs et al., 2009; Jacobs et al., 2012; Kiniwa et 
al., 2007; Olkhanud et al., 2011). Additionally, local myeloid cells are trimmed by TME 
to dconvert into myeloid-derived suppressor cells (MDSCs).  
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restore ζ-chain expression in T cells and significantly prolong survival of tumor-bearing 
mice (Meyer et al., 2011).  
Other approaches of T cell inhibition is the interaction of PD-1 expressed on T 
lymphocytes with PD-L1, which is expressed on tumor cells, MDSCs and Tregs (Jacobs 
et al., 2009; Ozao-Choy et al., 2009), Fig.5. PD-1 negatively regulates T cell responses 
through interaction of PD-1 with PD-L1, which leads to reduced proliferation and IFN-γ 
secretion (Freeman et al., 2000).  
 
1.4 Melanoma mouse model 
To develop new strategies of melanoma immunotherapy, it is essential to use a reliable 
animal melanoma model. Conventional transplantation mouse melanoma models (e.g., 
B16) are based on the transplantation of tumor cells, in which the natural history of the 
disease is not comparable with the clinical situation. Therefore, the ret transgenic mouse 
melanoma model, which closely resembles human melanoma with respect to tumor 
genetics, histopathology and clinical development is the better choice (Kato et al., 1998; 
Umansky et al., 2008). In this spontaneous transgenic melanoma model, the human ret 
receptor tyrosine kinase is overexpressed in melanocytes under the control of the mouse 
metallothionein-I (MT) promoter-enhancer. Activation of ret kinase overexpression 
during tumor progression is associated with the activation of other downstream signaling 
molecules such as mitogen-activated protein kinase (MAPK), Erk2 and c-Jun. During 
the malignant stage, tumors showed as well a high activity of matrix metalloproteinases 
(MMP)-2 and MMP-9 (Kato et al., 1998; Kato et al., 2001).  
The mechanism of spontaneous melanoma development in ret transgenic mice is still 
under investigation. So far is known that ret kinase overexpression during tumor 
progression is associated with the activation of other downstream signaling molecules 
such as mitogen-activated protein kinase (MAPK), Erk2 and c-Jun (Kato et al., 1999). 
During the malignant stage, tumors showed also a high activity of matrix 
metalloproteinases (MMP)-2 and MMP-9 (Kato et al., 1999; Kato et al., 2001; Kato et 
al., 2006; Phay and Shah, 2010).  
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Mice develop spontaneously malignant cutaneous melanoma, metastasizing to lymph 
nodes, lungs spleen, kidney, liver and brain (Kato et al., 1998; Kato et al., 2004). This 
metastatic profile resembled that of human malignant (Polsky et al., 2002).  
 
1.5 Aim of the study 
Melanoma is known to be very aggressive and associated with high lethality rates once it 
metastasized. It shows poor response to common treatments. Therefore, the investigation 
of novel therapeutic strategies is very important. Immunotherapeutic approaches are 
particularly promising because of the immunogenic properties of melanoma. 
The objective of this work is to determine whether melanoma-specific memory T cells, 
which have been previously shown to persist in the bone marrow of patients with 
different cancer types, can be utilized for an adoptive immunotherapy against melanoma 
in ret transgenic mice. Therefore, the phenotype and effector functions of in vitro 
activated melanoma-specific memory T cells from the bone marrow of ret transgenic 
mice were characterized in vitro. Furthermore, migration properties of these cells and 
their anti-tumor effect were examined in vivo. In addition, an adoptive transfer of 
melanoma-specific T cells with was performed after modulation of the tumor 
microenvironment with PDE-5 inhibitor sildenafil. 
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2 Materials 
2.1 Mice 
All mice were crossed and kept under specific pathogen-free conditions in the animal 
facility of the German Cancer Research Center (Heidelberg). Experiments were 
performed in accordance with government and institute guidelines and regulations.  
 
2.1.1 RET TRANSGENIC SPONTANEOUS MELANOMA MOUSE MODEL 
  Ret transgenic mice (C57BL/6 background) express the human Ret proto-oncogene in 
melanocytes under the control of mouse metallothionein-I promoter-enhancer. These 
mice were kindly provided by Dr. I. Nakashima (Japan) (Kato et al., 1998) and were 
kept under the guidelines of the animal facility of the German Cancer Research Center. 
 
2.1.2 TRP-2 TCR TRANSGENIC MOUSE MODEL 
Mice with T cell receptor transgene (TCR Tg) specific for the TRP-2(180-188) epitope were 
kindly provided by Dr. A. Hurwitz (USA), crossed and kept under the guidelines of the 
animal facility of the German Cancer Research Center. 
 
2.1.3 C57BL/6  
The C57BL/6 (BL/6) wild type mice were provided by Elevage Janvier, crossed and 
kept in the mouse facility of the German Cancer Research Center. 
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2.2 Reagents 
2.2.1 CHEMICALS 
3-Amino-9-ethyl-carbazol   Sigma, Cat.#A6926 
(AEC) tablets  
Ammonium chloride (NH4Cl) Merck,Cat.#101141 
Bovine serum albumin (BSA)       Sigma, Cat.#7030-50G 
Concanavalin A                            Amersham Biosciences, 
Cat.  170450-01 
Dimethylsulfoxid (DMSO)        Merck, Cat.#109678 
0,5M EDTA (pH 8.0)          GIBCO, Cat. #15575-098 
100% Acetic acid (CH3COOH)    Merck, Cat.#100063 
Fatal bovine serum (FBS)              PAN Biotech GmbH, Cat.#3702-    
        P260718 
Isofluran    DeltaSelect 
Potassium hydrogen carbonate Roth, Cat. #P748 
(KHCO3)    
Sodium acetate (CH3COONa)    neoLab, Cat.#4720 
Sodium azide (NaN3)       Roth, Cat.#K305 
Sodium carbonate (Na2CO3)    AppliChem, Cat.#A3900 
N,N – Dimethylformamid  Sigma, Cat. D-4551 
0.4% Trypan blue solution  Sigma, Cat.#T8154 
Tween20       Sigma, Cat. #P-2287 
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2.2.2 BUFFERS AND MEDIA 
Enzyme-linked immunosorbent spot (ELISPOT) 
AEC buffer      1 AEC tablet (20mg) 
      Dimethylformamide   2,5 ml 
      0,2M Sodium acetate  8,4 ml 
      0,2M acetic acid 3,5 ml 
      H2O bidest.         35,6 ml 
      Hydrogen peroxide      25 μl 
An AEC tablet (20 mg) was dissolved in 2.5 ml of dimethylformamide in a 50 ml Falcon 
tube. Then, 8.4 ml of 0.2 M sodium acetate, 3.5 ml of 0.2 M acetate acid and 35.6 ml 
H2O were added. After mixing, the solution was filtered through 0.45 m filter and 25 l 
of H2O2 was added. The prepared AEC buffer should be kept in dark and used within 
one month after preparation.  
 
Working solution     1x PBS 
      BSA, 0,5% (w/v) 
Coating buffer   
Solution A:  1,59g Na2CO3 in 100 ml H2O 
Solution B:           2,93g NaH2CO3 in 100 ml H2O 
Working coating buffer    1 ml A + 1 ml B + 8 ml H2O  
pH 9.6 
Washing buffer    1x PBS, Tween 20, 0,25% (v/v) 
 
Flow cytometry (FACS) 
FACS buffer    1 x PBS   
2% FBS,  
0.2% NaN3  
2 mM EDTA 
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10x lysis buffer    8,29 g NH4Cl  
      1 g KHCO3  
      37,2 mg EDTA, disodium   
      ad 1 l H2O, pH (7.2-7.4) 
 
Dynal® mouse T cell negative isolation buffer 
Buffer 1     1xPBS  
0,1% BSA and  
2 mM EDTA, pH 7.4 
Buffer 2     RPMI-1640  
10% FCS 
 
2.2.3 MEDIA 
Complete RPMI-1640   w/L-glutamine, PAA Cat.# E15-840 
DC-Medium     445 ml RPMI-1640  
50 ml heat inactivated FCS   
(56°C; 45min) 
T cell medium RPMI-1640 w/L-glutamine, PAA Cat.# 
E15-840 
 5 ml P/S 
 5 ml Hepes 
 5 ml -Mercaptoethanol 
 50 ml FCS 
 
2.2.4 ANTIBODIES 
Antibodies for flow cytometry 
Antibody Format Reactivity Company/ cat.# 
anti-mouse CD8a PE rat IgG2a  BD 553033 
APC-Cy7 rat IgG2a  BD 557654 
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APC-H7 rat IgG2a  BD 560182 
Alexa Flour 
47
rat IgG2a  BioLegend  
anti-mouse CD3 PerCP-Cy5.5 rat IgG2a  BD 555276 
APC rat IgG2a  BD 553066 
FITC rat IgG2a  BD 553062 
V500 syrian hamster IgG2  BD Horizon  
Apacific blue syrian hamster IgG2  BD 558214 
anti-mouse CD45RB FITC rat IgG2a  BD 553100 
anti-mouse CD62L FITC rat IgG2a  BD 553150 
APC rat IgG2a  BD 553152 
anti-mouse I-A/I-E FITC rat IgG2a  BD 553623 
anti-mouse CD4 PE rat IgG2b  BD 553730 
pacific blue rat IgG2b
 
BioLegend 
anti-mouse CD40 PE rat IgG2a  BD 553791 
anti-mouse CD44 PE rat IgG2b  BD 553134 
FITC rat IgG2b  BD 561859 
PE-Cy7 rat IgG2b  eBioscience 
Anti-mouse CD69 Alexa Flour 
47
armenian hamster IgG BioLegend 
APC-Cy7 armenian hamster 
I G
BD 561240 
PE-Cy7 amenian hamster IgG BioLegend 
anti-mouse CD80 (B7.1) PE hamster IgG2 k BD 553769 
anti-mouse CD86 (B7.2) PE rat IgG2a  BD 553692 
Anti-mouse CD45.2 V500 rat IgG2a  BD Horizon 
PerCP-Cy5.5 IgG2a, κ BD 552950 
CD279 (PD-1) FITC armenian hamster IgG eBioscience 
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PE armenian hamster IgG eBioscience 
CD274 (B7-H1, PD-L1)  PE rat IgG2a λ BD 558091 
Table 2: Antibodies for flow cytometry 
 
ELISPOT 
 Name Reactivity Clone Company/cat. #
Primary 
antibody 
IFNγ rat anti-
mouse 
RMMG-1 Biosource Europe 
AMC 4834 
Secondary 
antibody 
IFNγ, 
biotinylated 
rat IgG1, κ XMG1.2 BD 554410 
Streptavidin-
HRP   
- - - BD 557630 
Table 3: Antibodies used for ELISPOT 
 
Other antibodies/ Dextramer/ peptides 
 
Antibody Format Reactivity Company/ cat.#
anti-mouse CD274 (B7-
H1) 
purified rat IgG2a, λ eBioscience 
14-5982-82 
  rat IgG2b, κ BD 553142 
Table 4: Other antibodies 
 
 Format Allele Peptide Company/ cat.#
MHC -Dextramer PE H-2 Kb SVYDFFVWL Immudex JD2199
TRP-2(180-188) 
peptide 
purified  SVYDFFVWL DKFZ Heidelberg
Table 5: TRP-2 Dextramer and peptide 
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2.3 Kits  
T cell enrichment Dynal® Mouse T Cell Negative Isolation Kit, 
Invitrogen, Cat. #114.13 
IFN-γ  secretion assay      Mouse IFN-γγ Secretion Assay – Cell 
Enrichment and Detection Kit, Miltenyi, 
Cat. # 130-090-517 
 
2.4 Routine laboratory materials 
2.4.1 DEVICES 
ELISPOT Reader           Bioreader 3000, Biosys 
FACS machine         FACS Canto II, 8 colors, BD 
Refrigerator (-80 °C)    HeraFreeze, Heraeus 
Incubator              HeraCell, Heraeus 
Refrigerator (-20 °C)            Premium, Liebherr 
Microscopes          DMIL, Leica 
pH meter                766, Calimatic 
Laminar flow              Hera Safe, Thermo Electron Cooperation 
Vortex                REAX top, Heidolph 
Vortex Genie 2, Scientific Industries 
Balance     BP 3100P, Sartorius 
Water bath               DC3, HAAKE / GFL 
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Centrifuges                  Labofuge 400R, Heraeu 
Biofuge primo R, Heraeus 
                Varifuge K, Heraeus 
 
2.4.2 ROUTINE LABORATORY MATERIALS 
ELIPOT plates Silent Screen Plate 96-well clear w/o Lid 
Biodyne B Membrane N/Str PS, Nunc, Cat. 
# 256154  
Needles                 0,4x19 mm Mikrolance, BD 
               0,3x13 mm Mikrolance, BD 
Pipets 2-20 μl, 20-200 μl, 200-1000μl, Rainin 
Object carrier           76x26 mm SuperFrostPlus, 
                   Menzel-Gläser, Cat. J1800AMNZ 
Cover glass                      24 x 24 mm , Roth 
Tubes 15 ml / 50 ml            Polypropylen, BD Falcon   
0.5 ml tubes, Eppendorf  
1.5 ml tubes, Eppendorf  
2 ml tubes, Eppendorf  
Syringes                 1 ml Plastipak, BD 
             
Cell culture plates       96-well-Platte, Greiner 
               24-well plate, TPP 
                   6-well plate, Greiner 
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Cell strainer       40 μm; 100 μm, BD Falcon 
Sterile filter  0,45 μm, sterile, Rotilabo, Roth  
 
2.4.3 SOFTWARE FOR DATA ANALYSIS 
FlowJo (Version 7.6.1)   Tree Star, Inc., Ashland, USA 
GraphPad PRISM (Version 5) GraphPad Software, Inc., San Diego, USA 
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3  Methods 
3.1 Preparation of single cell suspensions from mouse 
organs 
Mice were sacrificed by cervical dislocation. 
 
3.1.1 SPLEEN 
Mouse spleens were collected in 15 ml Falcon tube with 2 ml of ice-cold PBS. Single cell 
suspensions were prepared by smashing the spleen with the plunger of a 5 ml syringe 
through a 40 μm cell strainer. Then the cells were washed with cold PBS once at 1200 
rpm for 10 min. Red blood cells were lysed with 1 ml of lysis buffer on ice for 3 min 
followed by the addition of 9 ml PBS to stop the reaction. Cells were centrifuged (1200 
rpm, 10 min) and the cell pellets were resuspended in appropriate buffers for different 
assays. 
 
3.1.2 LYMPH NODES 
Isolated mouse lymph nodes were smashed through a 40 μm cell strainer using plunger of 
a 5 ml syringe. The cell strainer was washed with cold PBS to remove the remaining 
cells. The cells were washed with PBS once at 1200 rpm, 10 min and resuspended in 
FACS buffer for flow cytometry. 
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3.1.3 BONE MARROW 
Freshly isolated femurs and tibiae from the mouse were shortly treated with 70% ethanol 
to avoid contamination. Then the bones were cut at both ends and the BM was flushed 
with ice cold PBS using a 10 ml syringe with a 23G needle. The cells were collected in a 
10 cm Petri dish and dissociated by pipetting with a 1 ml pipette. Then, cells were 
washed once with PBS and red blood cells were lysed with 1 ml of lysis buffer for 3 min 
on ice. After washing with cold PBS Cold PBS (1200 rpm, 10 min), the pellet was 
resuspended in an appropriate buffer depending on the following assay. 
 
3.1.4 TUMOR 
The freshly isolated tumor mass was smashed through a 40 μm cell strainer by a 5 ml 
syringe plunger into a 50 ml Falcon tube. Cells were washed with cold PBS at 1200 rpm 
for 10 min. The cell pellet was resuspended in an appropriate buffer. 
 
3.1.5 ASSESSMENT OF CELL CONCENTRATION 
The cell number was determined using a Neubauer counting chamber. A sample of 10 μl 
was diluted with trypan blue in a ratio 1:100 and two quadrates were counted and 
divided by two to attain a precise number of cells. The following formula was used: 
n x 104 x dilution factor (10) = cell number / ml 
 
3.2 Generation of bone marrow derived dendritic cells  
3.2.1 DC CULTURE 
DC were generated from BM precursors of C57BL/6 mice. A single cell suspension from 
the BM was prepared as described and resuspended in RPMI-1640 medium 
supplemented with 10% FCS and 1% P/S (complete medium). To deplete all adherent 
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non-DC precursors, cells were incubated in a 75 cm2 flask overnight at 37°C, 5% CO2 
and 95% humidity. Then the supernatant containing precursor cells was removed, 
washed with RPMI-1640 + 10% FCS and 1% P/S. After centrifugation the pellet was 
washed with RPMI-1640 + 10% FCS and 1% P/S and resuspended in complete 
RPMI-1640 medium (1x106/ml). 1000 U/ml of recombinant murine GM-CSF (rmGM-
CSF) and 1000 U/ml of recombinant murine IL-4 (rmIL-4) were added. Three ml of the 
cell suspension was plated in each well of a 6-well plate followed by a 7 days culture at 
37°C, 5% CO2 and 95% humidity. On day 3 and 6, 1.5 ml of medium from each well 
were carefully removed, collected in a 50 ml Falcon tube and centrifuged (1300 rpm, 5 
min). Next the pellet was resuspended in the same volume of complete RPMI-1640 
medium. GM-CSF and IL-4 were added (each 1000 U/ml), and the wells were filled with 
freshly prepared medium. The day before DC harvesting, DC were activated with 3 
μg/ml of CpG1668 phosphorothioate (PTO)-modified. In addition, the PD-L1 on DC 
was blocked with 10 μg/ml of purified anti-PD-L1 antibody. DC were pulsed with 500 μg 
tumor lysate per well overnight. The pulsing of stimulated DC with TRP-2 derived 
peptide (TRP-2180-188) was performed for 2 hours. Then, DC were harvested by carefully 
pipetting and collected in a 50 ml Falcon flask for further procedures. 
 
3.2.2 PHENOTYPE ANALYSIS OF DC  
DC phenotype was detected by flow cytometry. In order to avoid unspecific binding of 
the antibodies to the Fc receptor, cells were incubated for 15 min with Fc block solution. 
After washing with FACS buffer samples were incubated with mAbs against MHC class 
II-PE, CD11c-APC, CD40-FITC, CD80-PerCP/Cy5.5 and CD86-PE-Cy7 for 30 min at 
4°C in the dark followed by two washing steps and resuspension in 200 μl of FACS 
buffer. 
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3.2.3 PREPARATION OF TUMOR LYSATES 
In order to make intracellular proteins accessible for DC pulsing with tumor antigens, 
tumor cells were lysed by mutual  freezing in liquid nitrogen and thawing at 37°C 
(Feuerer et al., 2001a).  
The tumors were squeezed through 45 μm cell strainers and collected in a petri dish with 
2 ml of ice cold PBS. The suspension was collected in a preferably small amount of PBS 
(1-2 ml/tumor) so that in the end a high concentration of the protein was attained. The 
suspension was transferred into a 15 ml flask and flash-frozen for 10 min in liquid 
nitrogen. Then the cells were thawed at 37°C in water bath for another 10 min. This 
procedure was repeated four times.  Afterwards the cell debris was centrifuged (2000 
rpm, 7 min, 4°C), the supernatant containing protein was transferred into 2 ml 
Eppendorf tubes and the tumor lysates (TL) were frozen at -80°C until use. The protein 
concentration was analyzed by Bradford Assay according to manufacturers’ instruction.   
 
3.3 Negative selection of T cells from the bone marrow 
of ret transgenic mice 
The negative T cell isolation kit is based on a monoclonal antibody cocktail which binds 
all non-T cells like B-and NK cells, monocytes, macrophages, granulocytes and DC. 
Magnetic beads are bound to these antibodies and the bead-bound cells can be 
subsequently separated on a magnet and discarded. The benefit of this method is that 
the untouched T cells in the remaining eluate are not stimulated and can be used for 
further experiments. 
The negative selection of T cells from the BM of at least 10 mice was performed using 
the Dynal® Mouse T Cell Negative Isolation kit according to manufacturer’s protocol. 
Then the cells were counted, washed with PBS and the pellet was resuspended in 
complete medium. Then, cells were adjusted to an appropriate concentration for the co-
culture with DC.  
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3.4 Co-culture of T cells with dendritic cells 
3.4.1 CO-CULTURE 
In order to stimulate melanoma antigen-specific T cells from the bone marrow of ret 
transgenic mice, they were co-cultured with tumor antigen loaded DC as described in 
6.2.1. Within 40 hours of co-culture, only T cells, which already encountered tumor-
specific antigens (memory T cells), can be stimulated. The co-culture was performed in 
96-well plates (round-bottom).  
For the stimulation of memory T cells 5x105 freshly isolated T cells (6.3) were cultured 
with 1x105 in vitro generated tumor antigen-loaded DC (6.2.1) in 150 μl of complete 
medium per well (T cell: DC ratio= 5:1) at 37°C, 5% CO2 and 95% humidity. DC were 
derived from the BM progenitors of C57BL/6 wild type mice. After 40 h of co-culture 
cells were harvested by carefully pipetting and used for flow cytometry or adoptive 
transfer experiments. 
 
3.4.2 T CELL EXPANSION 
To detect optimal conditions for in vitro activation and expansion of memory T cells, a 
cytokine cocktail containing IL-21 (25 ng/ml), IL-15 (50 ng/ml) and IL-7 (10 ng/ml) was 
added to the co-culture on day 2 and the medium was exchanged every 2-3 days with 
fresh cytokines. 
 
3.5  Generation of TRP-2-specific CD8+ effectors 
For generation of TRP-2-specific CD8+ T cells, pooled lymph node cells and splenocytes 
from TCR tg mice were cultured in T cell medium with 1 μM of TRP-2(180-188) peptide 
and human recombinant IL-2 (20 IU/ml, PeproTech)for 3 days. Then, cells were 
expanded with media containing 20 IU/ml IL-2 for another 2 days. On day 5, cells were 
centrifuged, adjusted to a number of 1x107 cells in 100 μl and injected into tumor-
bearing ret transgenic mice. In case of migration experiments, cells were stained with 5-
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(and 6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) before the adoptive 
transfer as described by Parish CR, et al. (2009). Therefore, 1x107 cells were 
resuspended in 0.5 ml PBS supplemented with 10% FCS (PBS-10%FCS) and 0.5 ml 
CFSE solution (1 μM solution: 2 μl from 5 mM CFSE stock solution mixed with 10 ml 
PBS). Then, cells were incubated at 37°C for 10 min, gently shaken and 4 ml of pre-
warmed PBS-10% FCS was added to stop the reaction. Cells were washed in PBS (1400 
rpm, 8 min, 4°C) and resuspended in pre-warmed sterile PBS and counted.    
 
3.6  Flow cytometry 
Flow cytometry allows the simultaneous multiparametric analysis of single cells based on 
the emission of electronic light when a cell passes the electronic detection apparatus. The 
fluid containing cells which are labeled with fluorescent markers are sucked through a 
capillary and are focused in the center. Thereby, the cell aggregates are dissolved by the 
strong acceleration which allows the passage through a laser beam of a single cell. The 
cell that passes the laser beam emits scattered light, which is dependent on the size, 
structure of the cell membrane and the intracellular content of the cell. Two different 
scatterings exist, the forward scatter (FSC) which contains information about the size 
and the side scatter (SSC) that is a measure for granularity of the cell (Baumgarth,N. 
2000, Radbruch, 2000). Since the emitted fluorescence is proportional to the amount of 
antibody-bound epitopes, with the help of fluorescent markers phenotype of the cell can 
be determined. The more antigens are expressed on the cell bound to the antibody the 
stronger is their emission of the light. Different fluorescent dyes have different absorption 
and emission spectra which allows staining of different epitopes of a cell.   
 
3.6.1 STAINING OF CELL SURFACE MARKERS  
1x106 cells/well cells were transferred into a 96-well plate (round bottom). After 
centrifugation (1900 rpm, 1 min) the supernatant was discarded and the pellet was 
resuspended in 50 μl of FACS buffer containing Fc-block. After 15 min of incubation at 
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4°C cells were washed with 150 μl/well FACS buffer and centrifuged (1900 rpm, 1 min). 
Afterwards, the cell pellet was resuspended in 50 μl FACS buffer containing fluorescent-
conjugated antibodies (list of used antibodies see 2.2.4). The cells were incubated for at 
least 20 min at 4°C in the dark. Before measurement the cells were washed twice with 
FACS buffer and the pellet was resuspended in 10-200 μl FACS buffer. The 
measurement was performed with the FACSCanto II (BD) using the BD Diva Software 
V.6.1.1. FlowJo software 7.6.1 (Tree Star) was used to analyze at least 100,000 events. 
Data were expressed as dot plots.  
 
3.6.2 MHC DEXTRAMER STAINING OF TRP-2-SPECIFIC CD8 T CELLS 
The MHC Dextramer staining is based on the interaction of the TCR on T cells and 
MHC complex on antigen-presenting cell (APC). The multimer staining technique was 
developed by Altman et al. (1996). It enables the detection of antigen-specific T cells ex 
vivo. MHC multimers are reagents that carry multiple MHC-peptide complexes. They 
have the ability to bind simultaneously to multiple TCRs on a single T cell. The antigen 
which the MHC complexes contain is the TRP-2 derived peptide180-188 (SVYDFFVWL). 
 
 
Fig.6: Schematic drawing of the MHC Dextramer. Source: Immudex, Denmark 
After the Fc-block cells were incubated with 10 μl of PE-labeled MHC Dextramer for 10 
min at 4°C in the dark. Then antibodies for CD8 T cells were added followed by 
incubation for another 20 min. Then the cells were washed with FACS buffer twice and 
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the pellet was resuspended in 100-200 μl FACS buffer for the measurement using 
FACSCanto II. 
 
3.7 IFN-γ ELISPOT 
3.7.1 PRINCIPLE OF THE ASSAY 
ELISPOT assays have an unsurpassed sensitivity in detecting low frequency antigen-
specific T cells that secrete effector molecules, including granzyme and perforin 
(Lehmann et al. 2012). This assay provides an effective method of measuring antibody or 
cytokine production of immune cells on a single cell level (Janeway et al. 2002).  
Fig.7 shows the principle of ELISPOT. For the detection of cytokines released by 
stimulated T cells micro titer plates with a nitrocellulose bottom are coated with an 
antibody against the cytokine of interest. Then, cells are incubated in the coated wells. 
During incubation, the cells secrete cytokines which bind to the coating antibodies in the 
area of secretion. After incubation, the cells are removed and biotinylated secondary 
antibodies and streptavidin-bound enzyme conjugates are added. After incubation, a 
substrate is given. The spots, which appear during the development of the assay, 
represent a single cell secreting the cytokine of interest (Schmittel et al., 2000).  
 
Fig.7: Principle of ELISPOT.1. Coat membrane with antibodies. Add immune cells and 
incubate. 2.Responding cells produce cytokines. The cytokine of interest is then bound by the 
antibody.3 Wash to remove cells. Add biotinylated antibodies which bind to the cytokine-
antibody complex. 4 Add avidin-enzyme conjugate. 5 Add enzyme substrate and each 
responding cell will result in one spot. 
http://www.millipore.com/immunodetection/id3/elispot 
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3.7.2 IFN-γ PRODUCTION BY STIMULATING BM T CELLS 
In order to demonstrate the functionality of BM-derived memory T cells, a co-culture 
with antigen pulsed DC was performed (see 3.4). The co-culture was made in an 
ELISPOT plates that were equilibrated with 15 μl 70% ethanol for 1 min, washed twice 
with 200 μl/well PBS and coated with rat anti-mouse IFN-γ  primary antibody (10 μg/ 
ml in coating buffer; 100 μl/well). The plates were sealed with parafilm and incubated at 
4°C over night.   
At the same day, DC were stimulated, treated with anti-PD-L1 and pulsed with antigen 
(see 3.2.1). 
One day later, the unbound antibody was washed off twice with 200 μl/well of sterile 
water. The membrane was blocked with 150 μl/well RPMI-1640 supplemented with 10% 
heat inactivated FCS for at least 2 h at 37°C. The blocking medium was decanted and 
5x105 freshly separated T cells were cultured with 1x105 generated DC per well (T 
cell:DC ratio of 5:1) in 150 μl complete medium. For positive controls, BM-derived T 
cells and splenocytes were treated with concavalin A (ConA, 10 mg/ml). The plates were 
incubated for 40 h at 37°C, 5% CO2 and 95% humidity. 
Then cells were washed 6 times with PBS/0,05% Tween®20 (PBS-T), incubated with 50 
μl/well biotinylated IFN-γ  secondary antibody (rat anti-mouse, 1 μg/ml in sterile BSA 
buffer) for 2 h at 37°C, 5% CO2 and 95% humidity. Plates were washed again 6 times 
with PBS-T and incubated with diluted streptavidin-HRP (1:500 in PBS, 100 μl/well) 
for 2 h at 37°C followed by  washing three times with PBS-T and three times with PBS. 
For the spot development, AEC substrate was freshly prepared (see 2.2.2). Spot 
development was started after the addition of 50 μl/well AEC substrate and incubation 
for 3-10 min at RT in the dark. The reaction was stopped under running water and 
extensive washing. Plates were dried between paper towels overnight. The quantification 
of the spots was analyzed in the ELISPOT reader Bioreader®-3000 (BioSys).   
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3.8 IFN-γ  secretion assay  
3.8.1 PRINCIPLE OF THE METHOD 
In addition to ELISPOT, antigen-specific IFN-γ secretion by T cells can be detected with 
the Mouse IFN-γ Secretion Assay Detection Kit (Miltenyi Biotec). The cells are re-
stimulated either with APCs or with a peptide followed by attachment of the IFN-γ-
specific Catch Reagent to the cell surface. During the IFN-γ secretion phase, IFN-γ binds 
immediately to the Catch Reagent on the secreting lymphocytes. Then these cells are 
labeled with the IFN-γ Detection Antibody conjugated to a fluorescent dye. The IFN-
γ secretion can be detected in different T cell subsets. Analysis of IFN-γ secreting T cells 
is performed by flow cytometry. 
For the detection of IFN-γ secreting CD8 T cells in the T cell-DC co-culture the IFN-
Secretion Assay Detection Kit (APC*) was used according to manufacturer’s 
instructions. T cells were co-culture with DC for 40 h as described in 3.4 followed by a 
staining with anti-CD3 and anti-CD8 fluorescent labeled antibodies. T cells cultured 
without DC were taken as a negative control. Con A or staphylococcal enterotoxin B 
(SEB) was added to splenocytes for unspecific stimulation and IFN-γ secretion as a 
positive control. Propidium iodide (PI) was added directly before measurement to 
exclude dead cells.  
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3.10  Statistical analyses  
Statistical analyses were performed using Excel 2007 (Microsoft) and GraphPad Prism 5 
(GraphPad Software, Inc.). Results were expressed as mean±SD. To determine 
significant differences between two groups, P values were calculated by unpaired t-test. 
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Cells, which express CD11c, were considered as mature DC. Around 76% of the cells in 
culture expressed CD11c and 19% CD11c and MHC-II (double positive). Out of CD11c+ 
cells, 25% expressed CD40, 73% CD80 and 92% CD86. Hence, the majority of CD11c+ 
cells expressed co-stimulatory molecules, which is important for T cell activation. 
 
4.2  T cells from the bone marrow of ret transgenic mice  
4.2.1 T CELL FUNCTION OF MEMORY T CELLS EX VIVO 
Next, we determined the anti-tumor reactivity of memory T cells, which were isolated 
from the BM of ret transgenic mice with macroscopic tumors or without visible tumors. 
Bone marrow-derived T cells were co-cultured for 40 h with DC loaded with tumor 
lysate or TRP2(180-188) peptide (see 3.4). Such short-term co-culture is enough to activate 
tumor-specific memory T cells but is not sufficient to stimulate their naive counterparts.  
It is known that the interaction between PD-1 on T cells and PD-L1 on DC can 
negatively regulate the T cell immune response (Fourcade et al., 2010; Freeman et al., 
2000). Moreover, the blockade of PD-L1 leads to an enhanced therapeutic efficacy of the 
immunotherapy against melanoma (Pilon-Thomas et al., 2010). In order to block PD-
1/PD-L1 interaction during the co-culture of T cells with DC, the latter were pretreated 
with anti-PD-L1 antibodies prior to co-culture (6.4.1). IFN-γ secretion was measured 
using the ELISPOT assay.  
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Fig.10: ELISPOT. DC were generated in vitro from BM progenitors of non-transgenic 
C57BL/6 mice in complete RPMI-1640 medium supplemented with rmGM-CSF (PeproTech) 
and rmIL-4 (eBioscience) (1000 U/ml each). Immature DC were stimulated with CpG and 
treated with anti-PD-L1 antibodies (eBioscience), where indicated, followed by pulsing with 
whole tumor lysate for 20 h or with TRP-2 derived peptide (TRP-2180-188) for 2 h. DC were 
co-cultured with freshly isolated CD3+ T cells from the BM of ret transgenic tumor free (tg) 
or tumor-bearing (tb) mice (DC:T cell ratio, 1:5) for 40 h. The secretion of IFN-γ was 
measured by ELISPOT assay. The graph shows the results of two independent performed 
assays (each in triplicates).  
After co-culture with DC pulsed with tumor lysate or TRP-2(180-188) peptide, T cells were 
able to secrete IFN-γ (Fig.10). The amount of IFN-γ secreting T cells from mice without 
visible tumors (tg) was similar after DC pulsing with tumor lysate or TRP-2(180-188) 
peptide. In contrast, DC pulsed with TRP-2(180-188) peptide induced higher amounts of 
IFN-g producing T cells isolated from tumor-bearing (tb) mice than DC pulsed with 
tumor lysate. After PD-L1 blockade on DC, the number of IFN-γ secreting T cells from 
tg mice was significantly increased both upon the co-culture with DC loaded with the 
peptide or tumor lysate. On the other hand, the pretreatment of DC with anti-PD-L1 
antibodies did not lead to an enhancement of IFN-γ secreting T cells in tb mice if DC 
were pulsed with the TRP-2(180-188) peptide. Therefore, the pretreatment of DC with anti-
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PD-L1 antibodies leads to an increase of IFN-γ secretion in T cells upon stimulation with 
melanoma antigen-pulsed DC.  
To confirm our results with ELISPOT assay, we used the IFN-γ secretion assay. In this 
setup, IFN-γ secretion of T cells from mice without visible tumors was detected after in 
vitro stimulation with DC pretreated with anti-PD-L1 antibodies and pulsed with 
TRP2(180-188) peptide before co-culture (see 6.4.1).  
 
Fig.11: IFN-γ secretion assay. DC were generated in vitro from BM progenitors of non-transgenic 
C57BL/6 mice in complete medium supplemented with rmGM-CSF and rmIL-4 (1,000 U/ml each). 
Immature DC were stimulated with CpG and treated with anti-PD-L1 antibodies, followed by pulsing with 
TRP-2 derived peptide (TRP-2180-188) for 2 h. DC were co-cultured with freshly isolated CD3+ T cells 
from the BM of ret transgenic tumor free mice (DC:T cell, 1:5). After 40 h, the secretion of IFN-γ was 
measured using the IFN-γ secretion assay. As a negative control (C), T cells were cultured for 40 h in the 
absence of DC confirming that the secretion depended on the presence of DC.  
Fig.11 shows the proportion of IFN-γ secreting T cells after co-culture with TRP-2(180-188) 
peptide pulsed DC either pretreated with anti-PD-L1 antibodies or without the 
pretreatment. After PD-L1 blockade, we detected more IFN-γ secreting T cells as 
compared with the co-culture without anti-PD-L1 pretreatment (5,42% vs. 3,22%). 
These data confirms that the PD-L1 blockade on DC prior to co-culture leads to an 
increased stimulation of T cells. 
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4.2.2 T CELL EXPANSION 
Since for an adoptive transfer an efficient amount of melanoma-antigen-specific T cells is 
required, the T cell expansion was initiated (5x105 T cells and 1x105 DC). The absolute 
amount of cells decreased during the culture (data not shown). However, a relative 
enrichment of CD3+ and CD8+ T cells could be observed (Fig. 12A). The number of 
CD4+ T cells remained stable during the co-culture. At day 2, we observed no changes in 
the frequency of central and effector memory as well as naive subsets within total CD8+ 
T cells (Fig. 12B). Afterwards, the relative proportion of naive T cells within CD8+ T 
cells increased considerably, whereas the proportion of memory T cells diminished. CD4+ 
T cells showed a decrease in the memory phenotype and an increase of naive T cells 
already from the beginning of the co-culture (data not shown). 
The proportion of the early activation marker CD69 expressed on CD8+ T cells in the 
co-culture increased from 13,9% ± 1,8% at day 0 to 42,1% ± 5,4% at day 2 (Fig. 12C). 
Then, the percentage of CD69 expressing CD8+ T cells increased to 11,5% ± 7,2% at day 
8. In contrast, the proportion of CD4+ T cells with an activated phenotype was 
decreased.  
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Fig. 12: Phenotypical analysis of co-cultured T cells.CD3+ T cells were separated from the BM of ret 
transgenic mice with or without visible tumors, co-cultured with BM derived in vitro generated DC (T 
cell:DC-ratio, 5:1) and analyzed at the depicted time points. A) Relative amounts of CD3+, CD3+CD8+ and 
CD3+CD4+ cells during the co-culture. B) Proportions of MTC subpopulations within CD8+ T cells. C) 
Relative amounts of CD69 expressing CD4+ and CD8+ T cells during co-culture. D) Frequencies of 
exhausted (PD-1+) CD4+ and CD8+ T cells. 
Furthermore, no accumulation of exhausted (PD-1+) T cells occurred during the co-
culture (Fig. 12D). The amounts of PD1+ T cells was approximately the same for both T 
cell subsets at all measured time points remaining below 10% of total T cells.  
 
Fig.13: TRP-2-specificity of CD8+ T 
cells.Proportion of TRP-2 specific within 
total CD8+ T cells is shown. 
 
 
 
 
TRP-2-specific CD8+ cells
day0 day2 day6 day8
0
10
20
30
40
50
%
 o
f t
ot
al
 C
D
8+
 c
el
ls
Resu
 
Fig.1
prop
differ
1,7%
day 2
Base
adop
 
4.2.3
T ce
In to
40 m
cells,
cultu
The 
Ther
± 6.5
Fig.1
separa
lts 
3 depicts 
ortion of m
ent time p
 on day 0 u
, the TRP-
d on these 
tive transfe
  PHE
OF R
ll purity a
tal, 2,2x109
ice (n=6). 
 which wer
re.  
average of 
efore, the t
% of freshl
4: CD3+ T 
ted using Dy
the TRP-
elanoma-s
oints. The 
p to  32,8%
2-specificit
data, T cell
r experimen
NOTYPE 
ET TRAN
fter enrich
 ± 0,8x109 
Using nega
e not activa
the T cell 
otal amoun
y separated
cell purific
nal® Mouse T
2-specificity
pecific T c
tumor-spe
 ± 9,6% a
y decreased
s restimula
ts.  
ANALYSI
SGENIC M
ment and 
bone marro
tive T cell 
ted by ant
amount in 
t isolated o
 alive cells
ation. CD3+
 Cell Negativ
 
 of CD8+
ells measu
cificity of T
fter 40 h of
 to 10% on
ted by mel
S OF T C
ICE AFTE
40 h of co
w cells cou
selection k
ibody bind
the BM of
f T cells w
(Fig.14B). 
T cells from
e Isolation Ki
 T cells 
red by De
 cells incr
 co-culture
 day 8.  
anoma anti
ELLS FRO
R IN VITR
-culture 
ld be isolat
it, we were
ing and cou
 ret transg
as 3x107 cel
 
 the bone m
t (Invitrogen)
during the
xtramer s
eased nota
. During th
gen-loaded 
M THE B
O RESTIM
ed from fem
 able to iso
ld be used 
enic mice w
ls that corr
arrow of ret 
. A) shows a 
 co-culture
taining var
bly from 3
e co-culture
DC were u
ONE MAR
ULATION
urs and ti
late untouc
for T cell-D
as around
esponds to
transgenic m
dot plot of C
52 
. The 
ied at 
,1% ± 
, after 
sed for 
ROW 
 
biae of 
hed T 
C co-
 5-7%. 
 56.9% 
 
ice were 
D3+ and 
Results  53 
 
 
CD8+ T cells before and after separation. B) represents the frequency of CD3+ T cells before and after 
separation as well as upon 40 h co-culture with melanoma-antigen pulsed DC.  
After co-culture with TL-loaded DC loaded with tumor lysate, we achieved around 
75,7% ± 6,1% CD3+ T cells within the total alive cells. Therefore, we could isolate from 
ret transgenic mice a sufficient amount of bone marrow CD3+ T cells that was increased 
after the stimulation with DC. 
 
Phenotype analysis of CD8+ T cells after coculture 
Fig.15A demonstrates different phenotype subsets within CD8+ T cells before and after 
co-culture with DC pulsed with tumor lysate.  
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Fig.15: Phenotype analysis after co-culture. CD3+ T cells were separated from the BM of ret 
transgenic mice with or without visible tumors, co-cultured with bone marrow-derived in vitro generated, 
tumor lysate-pulsed DC (T cell:DC-ratio, 5:1) followed by flow cytometry. A) T cell subsets within 
CD3+CD8+ T cells before and after co-culture. B) TRP-2 Dextramer staining. Different T cell subsets within 
TRP-2-specific CD8+ T cells are shown.  
Among freshly isolated T cells, CD8+ T cell subset shows a prevalence for naive 
phenotype. After stimulation with tumor lysate-loaded DC the relative amount of naïve 
T cells was decreased (from 38.4% ± 15.3% before co-culture to 0.2% ± 0.1% after 40 h 
of co-culture, Fig.15A). Furthermore, the relative amount of the central memory T cell 
subtype increased after stimulation (23.6% ± 4.6% vs. 75.2% ± 5.9% after co-culture). 
Comparing effector and effector memory phenotype before and after co-culture, we could 
not observe any significant difference within CD8+ T cells. However, we could detect an 
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increase in TRP-2-specific CM T cells (from 16.0% ± 10.0% to 64.9% ± 21.1%) after the 
stimulation with DC. Moreover, these cells dominated within the CD3+ CD8+ T cell 
subset.  
Summarizing, after the co-culture, mainly central memory T cells specific for the 
melanoma antigen TRP-2 were found.  
 
4.2.4 T CELL MIGRATION AFTER INTRAPERITONEAL INJECTIONS  
An adoptive immunotherapy against cancer can only be effective when the transferred T 
cells are able to migrate into tumor lesions, where they can display their cytotoxic 
activity. It is also important that T cells migrate into the secondary lymphoid organs 
where they can encounter a tumor-antigens presented by DC.  
We analyzed the migration properties of in vitro activated memory T cells in ret 
transgenic tumor-bearing mice after intraperitoneal (i.p.) injections. Before the transfer, 
one part of the cell culture, including DC, was analyzed by flow cytometry and the other 
part was labeled with CPD (see 3.9). At day 3, 5 and 7 after adoptive transfer of CPD-
labeled DC and T cells, the migration to tumor lesions, metastatic lymph nodes, BM and 
spleen was measured. One representative of 10 experiments is shown in Fig.1. 2x106 cells 
per mouse were injected i.p. (Fig.16) followed by the migration assessment. Some CPD-
labeled cells were found in tumor lesions at day 3 and 7 after injections (Fig.16A). 
However, at day 5, considerably less CPD+ cells could be detected in the tumor. This is 
one of two experiments, were CPD+ cells could be detected. In all other experiments, it 
was not possible to track any labeled cells (data not shown). In the lymph nodes (LN), 
some cells could be tracked only at day 7.  
The analysis of the cells in the peritoneal cavity (Fig.16B) revealed that most of the 
CPD-labeled cells were remaining at the injection site. About 95% of the CPD+ cells 
expressed CD3, out of which approximately 2.5% were CD8+. At day 5 after the 
injection, the relative amount of labeled cells in the peritoneal cavity was considerably 
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less. At day 7 after the inoculation, the proportion of CPD+ cells increased to 16.1% of 
alive cells in the peritoneum. 
Therefore, adoptively transferred cells showed migration properties but the main part of 
injected cells remained in the peritoneal cavity.  
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Fig.16: T cell migration after i.p. injections. CD3+ T cells were separated from the BM of ret 
transgenic mice with or without macroscopic tumors and co-cultured with BM derived in vitro generated DC 
(T cell:DC ratio, 5:1) for 40 h. The cells were labeled with CPD and injected i.p. into tumor-bearing mice. 
A) At day 3, day 5 and day 7 after the injection, the migration of the cells to primary skin tumors and to 
lymphoid organs (LN: lymph nodes, BM, spleen) was determined. The injection was performed with 2.0×106 
CPD-labeled cells/mouse (n=2). In B) non-migrating cells in the peritoneal cavity were assessed (graph right 
panel). 
4.2.5 T CELL MIGRATION AFTER INTRACARDIAC INJECTIONS 
Since the migration of adoptively transferred T cells was found to be non-efficient, we 
injected the cells intracardially (i.c.). Freshly isolated T cells from ret transgenic mice 
were co-cultured with tumor lysate-loaded DC for 40 h (see 3.4). Then, 3x106 CPD-
labeled cells in 100 μl of sterile PBS (sPBS) were prepared. I.c. injections were performed 
under the supervision of Dr. med. vet. Michaela Socher. At day 3, 5 and 7 the migration 
of CPD-labeled cells in tumor lesions, blood, lymph nodes, BM and the spleen was 
assessed (Fig.17).  
Fig.17A shows that the maximal migration of CPD+ cells into tumor lesions was 
achieved at day 5. As expected, we could detect a decrease of CPD+ cells in the 
peripheral blood (Fig.17B). Also in metastatic lymph nodes, labeled cells were present 
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(Fig.17C). In addition, we found migrated cells in lymphoid organs like the bone marrow 
and the spleen (Fig.17D-E).  
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Fig.17: T cell migration after i.c. injections. CD3+ T cells were separated from the BM of ret 
transgenic mice with or without macroscopic tumors and co-cultured with BM derived in vitro generated DC 
(T cell:DC ratio, 5:1) for 40 h. The cells were labeled with CPD and injected i.c. into tumor-bearing mice. 
At day 3, day 5 and day 7 after the injection, the cell accumulation in the primary skin tumors (A), blood 
(B), lymph nodes (C), bone marrow (D) and the spleen (E)) was determined. The injections were performed 
with 3.0×106 CPD-labeled cells in 100 μl/mouse (n=5). 
The absolute amount of migrated T cells in the tumor, LN, BM and the spleen was 
presented in Fig.18. We detected a significant increase of CPD-labeled cells, out of all 
leukocytes (CD45.2+), from day 3 (0.5x105 cells ± 0.04x105 cells) to day 7 (7.2x105 cells 
± 3.2x105 cells, Fig.18A) in the tumors of ret transgenic mice. In the lymphoid organs, 
the absolute amount of T cells remained more or less the same, except for the lymph 
nodes, where the absolute number decreased over time (33.7x105 cells ± 23.2x105 cells at 
day 3 vs. 4.2x105 cells ± 2.1x105 cells at day7, Fig.18C). 
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Fig.18: Absolute amount of CPD+ migrated cells.  (n=5 for each time point). Five mice per 
measured time point. CD3+ T cells were separated from the BM of ret transgenic mice with or without 
macroscopic tumors and co-cultured with BM derived in vitro generated DC (T cell:DC ratio, 5:1) for 40 h. 
The cells were labeled with CPD and injected i.c. into tumor-bearing mice. At day 3, day 5 and day 7 after 
the injection, the absolute amount of migrated cells into primary skin tumors (A) bone marrow (B), lymph 
nodes (C) and spleen (D) was determined. The injections were performed with 3.0×106 CPD-labeled cells in 
100 μl/mouse.  
These data indicate that the in vitro activated T cells can efficiently migrate into tumor 
lesions.  
 
4.2.6  PHENOTYPE ANALYSIS OF MIGRATED CELLS IN THE TUMOR 
To assess the phenotype of CPD-labeled CD8+ T cells in infiltrated tumors, cells were 
stained with antibodies against CD62L, CD44 and CD45RB.  
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Fig.19: T cell subsets within CD8+ T cells. CD3+ T cells were separated from the BM of ret transgenic 
mice with or without macroscopic tumors and co-cultured with BM derived in vitro generated DC (T 
cell:DC ratio, 5:1) for 40 h. The cells were labeled with CPD and injected i.c. into tumor-bearing mice. On 
day 3, day 5 and day 7 after the injection the migration of the cells into to primary skin tumors was 
determined. The injections were performed with 3.0×106 CPD-labeled cells in 100 μl/mouse (n=5). After 
single cell suspension, tumor cells were stained with fluorescence-labeled antibodies against CD45.2, CD3, 
CD8, CD44 and CD62L. The measurement was performed by flow cytometry. 
As displayed in Fig.19, at day 3 and 5 the distribution of different phenotypes within the 
CD8+ T cell subsets was not significantly different. However, at day 7 the relative 
amount of effector CD8+ T cells in the tumor increased from 14.1% ± 18.0% up to 68.3% 
± 13.5%.  
 
4.2.7  IMMUNOTHERAPY WITH ADOPTIVELY TRANSFERRED 
ACTIVATED TUMOR-SPECIFIC MEMORY T CELLS 
3x106 cells per mouse were i.c. into tumor-bearing ret transgenic mice. The control group 
was treated with PBS. After the transfer, melanoma development in mice was monitored 
every second day to assure that they were not paralyzed or the tumor exceeded a 
marginal size.  
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Fig.20: Survival of tumor-bearing mice after adoptive transfer. A) CD3+ T cells were separated 
from the BM of ret transgenic mice with or without macroscopic tumors and co-cultured with BM derived in 
vitro generated, tumor lysate-pulsed DC (T cell:DC ratio, 5:1) for 40 h. The cells were labeled with CPD and 
injected i.c. into tumor-bearing mice. The injections were performed i.c. with 3.0×106 cells/mouse in 100 μl. 
B) Seven days before AT mice were treated with sildenafil dissolved in drinking water (20 mg/d/kg).**:P < 
0.05. 
Fig.20 shows the effect of an adoptive cell therapy with in vitro activated T cells on the 
survival of tumor-bearing mice. Already at day 43 after the transfer, the survival of mice 
in the therapy group was significantly higher than in the control group (P < 0.005). In 
addition, the treated mice were more active than in the control group. Therefore, ret 
transgenic mice contained functionally active melanoma-specific memory T cells in their 
BM, which could be restimulated with melanoma antigen-loaded dendritic cells to exert 
anti-tumor effects in vivo. 
MDSCs are known to inhibit tumor-reactive T cells. Previously, it has been shown by 
our group that MDSCs were accumulated in melanoma lesions and lymphatic organs of 
ret transgenic tumor-bearing mice. Phosphodiesterase-5 inhibitor (PDE-5) sildenafil was 
shown to restore the T cell reactivity and to prolong the survival of tumor-bearing mice 
upon in vivo application (Meyer et al., 2011). Therefore, we performed an adoptive 
transfer of in vivo activated BM derived T cells in combination with sildenafil Fig.20B. 
One week prior to the cell therapy, sildenafil was given to mice with the drinking water 
until the end of the experiment. One of two representative experiments is shown.  
Fig.20 depicts the survival of tumor-bearing mice upon the adoptive transfer of activated 
T cells in combination with sildenafil. The overall survival was significantly increased in 
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the combinational therapy group compared to sildenafil treatment alone and mice 
treated with PBS (P < 0.05).  
Therefore, these results show an in vivo anti-tumor effect of bone marrow derived 
memory T cells from ret transgenic mice in combination with sildenafil treatment.  
 
4.3  TRP-2-specific effector T cells from TRP-2 TCR 
transgenic mice 
Tyrosinase-related protein 2 (TRP-2) is a melanogenic enzyme which is expressed by 
both melanocytes and melanomas (Wang et al., 1996). It is reported to be a candidate 
melanoma rejection antigen (Engelhard et al., 2002). 
Recently, mice bearing T cell receptor transgene (TCR Tg) specific for TRP-2(180-188) 
epitope have been developed to study the role of self-reactive CD8+ T cells in tumor 
immunity (Singh et al., 2009). Since the bone marrow of ret transgenic mice contains 5-
7% T cells and therefore about 40 mice are needed to inject 6 mice for one survival 
experiment, we decided to use the TRP-2 TCR transgenic mouse model as a source of 
TRP-2-specific T cells for adoptive immunotherapy.  
 
4.3.1 MIGRATION OF TRP-2-SPECIFIC EFFECTOR T CELLS 
We determined first the migration capability of in vitro activated TRP-2-specific effector 
T cells from lymph nodes and the spleen of TRP-2 TCR transgenic mice. Single cell 
suspensions from lymph nodes and spleens were prepared and cultured in presence of IL-
2 and TRP-2(180-188) peptide for three days followed by the expansion for another two days 
in presence of IL-2 (see 3.5). T cells were stained with CFSE and 1x107 cells were 
adoptively transferred into tumor-bearing ret transgenic mice i.c..  
As shown in Fig.21B, the accumulation of adoptively transferred cells could be observed 
in the tumor at all three investigated time points with a maximum at day 5 (0.97% ± 
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0.32% at day 3 vs. 4.38% ± 2.08% day 5 out of all CD45.2+ cells). Also in all other 
analyzed organs, migrated CFSE+ cells could be detected. However, there was no 
significant difference of the relative amount of tracked at different time points in all 
organs (Fig.21C-F).  
Blood
Da
y 3
Da
y 5
Da
y 7
0.0
0.5
1.0
1.5
2.0
2.5
%
 C
FS
E+
 c
el
ls
 (o
ut
 o
f C
D
45
.2
+ )
Spleen
Da
y 3
Da
y 5
Da
y 7
0.0
0.2
0.4
0.6
0.8
1.0
%
 C
FS
E+
 c
el
ls
 (o
ut
 o
f C
D
45
.2
+ )
Lymph nodes
Da
y 3
Da
y 5
Da
y 7
0.0
0.2
0.4
0.6
0.8
1.0
%
 C
FS
E
+  
ce
lls
 (o
ut
 o
f C
D
45
.2
+ )
Bone marrow
Da
y 3
Da
y 5
Da
y 7
0.0
0.5
1.0
1.5
%
 C
FS
E+
 c
el
ls
 (o
ut
 o
f C
D
45
.2
+ )
Tumor
Da
y 3
Da
y 5
Da
y 7
0
2
4
6
%
 C
FS
E+
 c
el
ls
 (o
ut
 o
f C
D
45
.2
+ )
B C
D E F
A
CD
8
PBS controlgated on CD3+ CD8+
CFSE
 
Fig.21: Migration of TRP-2-specific effector T cells. Lymph node cells and splenocytes from TRP-2 
TCR transgenic mice were cultured in T cell medium with 1 μM of TRP-2(180-188) peptide and human 
recombinant IL-2 (20 IU/ml, PeproTech) for 3 days. Then, cells were expanded with media containing 20 
IU/ml IL-2 for another 2 days. At day 5, T cells were stained with 5-(and 6)-Carboxyfluorescein diacetate 
succinimidyl ester (CFSE) before adoptive transfer. Then, 1x107 CFSE-labeled T cells were injected into 
tumor-bearing ret transgenic mice. At the indicated time points mice were sacrificed and the migration was 
analyzed by flow cytometry. A) A representative dot plot of lymph node cells at day 5, gated on CD3+ CD8+ 
T cells. CD45.2+ CFSE+ cells in the tumor (B), peripheral blood (C), lymph nodes (D), bone marrow (E) 
and spleen (F) were determined by flow cytometry. 
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With respect to the absolute amount of migrated TRP-2-specific T cells, we could 
observe a significant increase of CFSE+ cells in the tumor. Comparing day 3 with day 5, 
there was an 2.9-fold increase in the migration into tumor lesions (5.45x105 cells ± 
5.78x105 cells vs. 15.75x105 cells ± 4.5x105 cells; Fig.22A) and comparing day 3 with day 
7 (33x105 cells ± 8.49x105 cells), we could observe a 6–fold increase. In contrast, the 
absolute amount of CFSE+ cells in lymph nodes, bone marrow and the spleen was 
consistent during the analyzed migration period (Fig.22B-C).  
These data demonstrate the migration capability of in vitro generated TRP-2-specific 
effector CD8+ T cells from of TRP-2 TCR transgenic mice into tumor lesions and 
lymphoid organs.  
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Fig.22: Absolute amount of migrated TRP-2 TCR effector cells. Lymph node cells and splenocytes 
from TCR tg mice were cultured in T cell medium with 1 μM of TRP-2(180-188) peptide and human 
recombinant IL-2 (20 IU/ml, PeproTech) for 3 days. Then, cells were expanded with media containing 20 
IU/ml IL-2 for another 2 days. At day 5, T cells were stained with 5-(and 6)-Carboxyfluorescein diacetate 
succinimidyl ester (CFSE) before AT. Then, 1x107 CFSE-labeled T cells were injected into tumor-bearing ret 
transgenic mice. At the indicated time points mice were sacrificed and the migration was analyzed by flow 
cytometry in tumors (A), bone marrow (B), lymph nodes (C) and spleens (D). Three measured experiments 
with duplicates per measured time points are shown. 
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4.3.2 PHENOTYPE ANALYSIS OF CELLS MIGRATED INTO THE TUMOR 
To define the phenotype of migrated CD8+ T cells, single cell suspensions were stained 
with antibodies against memory markers (CD44, CD62L).  
The frequency of the effector memory cells within migrated CD8+ T cells in the tumor 
increased from day 3 (12.7% ± 10.5%) to day 5 (53.6% ± 24.3%; Fig.18). In addition, we 
found a decrease in the relative amount of central memory, naive and the effector T cells 
at this period of time.  
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Fig.23: CD8+ T cell subsets in the tumor. Splenocytes and lymph node cells from TRP-2 TCR 
transgenic mice were cultured in T cell medium with 1 μM of TRP-2(180-188) peptide and human recombinant 
IL-2 (20 IU/ml, PeproTech) for 3 days. Then, cells were expanded with media containing 20 IU/ml IL-2 for 
another 2 days. At day 5, T cells were stained with 5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester 
(CFSE) before adoptive transfer. Then, 1x107 CFSE-labeled T cells were injected into tumor-bearing ret 
transgenic mice. At day 3, 5 and 7 after AT the phenotype of migrated CFSE+ CD8+ T cells was analyzed. 
Data from three experiments with duplicates are shown. 
 
4.3.3 IMMUNOTHERAPY WITH ADOPTIVELY TRANSFERRED ACTIVATED 
TRP-2-SPECIFIC T CELLS FROM TRP-2 TCR TRANSGENIC MICE  
In the first experiment (Fig.24A), 1x107 in vitro activated TRP-2-specific effector CD8+ 
T cells were injected i.c. into tumor-bearing mice. We did not found statistically 
significant difference in survival as compared to the untreated group (PBS). However the 
median survival of the treated group was increased. 
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Fig.24: Effect of immunotherapy with TRP-2 TCR transgenic T cells on melanoma 
development in ret transgenic mice. 1x107 in vitro activated T cells were injected alone (A) or in 
combination with (B). In the control group, mice were injected with 100 μl of sterile PBS n=8 per group. 
Both experiments were performed twice. One of each experiment is shown.     
In the second experiment, tumor-bearing mice were additionally treated with the PDE-5 
inhibitor sildenafil, starting on day seven before the adoptive immunotherapy (Fig.24B). 
In the group that included sildenafil therapy and adoptive transfer of TRP-2-specific 
CD8+ T cells, we failed to observe statistically significant increase in mouse survival. 
However, we detected a tendency of increased survival in the group with combinational 
therapy.  
In summary, we could observe a migration of BM derived reactivated melanoma antigen-
specific memory T cells into tumor lesions. Moreover, a significantly prolonged survival 
of tumor-bearing mice upon the adoptive transfer of these cells could be detected.   
Discussion  65 
 
 
5  Discussion 
Malignant melanoma is one of the most aggressive forms of human cancer. In its 
metastatic stage, the lethality rate is very high, and its incidence is on the rise. 
Melanoma is resistant to common treatments such as chemotherapy and radiotherapy. 
Another therapeutic option, like the immunotherapy with high dose IL-2 comes with 
harmful side effects. Therefore, it is of importance to develop new strategies against 
malignant melanoma. Since melanoma is notorious to be immunogenic, multiple studies 
paid attention on developing therapies based on the modulation of hosts’ immune 
system. 
In the present study, we focused on adoptive immunotherapy in the ret transgenic 
melanoma mouse model. As described above, this model resembles clinical situation in 
metastatic melanoma patients.  
 
5.1 Activated T cells secrete more IFN-γ after PD-L1 
blockade on DC prior to their coculture with T cells 
in vitro 
It has been previously shown that memory T cells were located in the BM of breast 
cancer patients and patients with other cancer types (Feuerer et al., 2001b; Muller-
Berghaus et al., 2006; Schirrmacher et al., 2002; Schmitz-Winnenthal et al., 2005). 
Moreover, the reactivation of isolated memory T cells from the BM of breast cancer 
patients with DC has been demonstrated (Beckhove et al., 2004; Feuerer et al., 2001a).  
The reactivation of memory T cells from the BM of ret transgenic tumor-free mice and 
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mice with microscopic tumors with DC pulsed with tumor lysate has been also shown 
(Umansky et al., 2008). It has been reported that mature DC express PD-L1 on their 
surface, which can lead to T cell exhaustion upon binding to PD-1 (Gu et al., 2008; 
Pilon-Thomas et al., 2010; Schreiner et al., 2004).  Therefore, we examined the T cell 
response after restimulation with DC upon PD-L1 blockade. T cells were isolated from 
the BM of ret transgenic mice and the response was measured using an IFN-γ release via 
ELISPOT or IFN-γ capture assay. As expected, there was a significantly increased 
secretion of IFN-γ after PD-L1 blockade with anti-PD-L1 antibodies on DC prior to 
coculture as compared to the stimulation with untreated DC. An enhanced T cell 
activity after PD-L1 blockade on monocyte-derived DC has been previously observed 
(Brown et al., 2003).  
In summary, the activity of T cells from the BM of ret transgenic tumor-free and tumor-
bearing mice was enhanced after reactivation in vitro with DC treated with anti-PD-L1 
antibodies prior to coculture with freshly isolated T cells. 
 
5.2 T cell expansion 
An effective expansion of melanoma specific T cells is required to obtain a sufficient 
number of cells for immunotherapy. After the isolation of T cells from the BM of ret 
transgenic and the 40 h coculture with DC we added IL-21, IL-15 and IL-7 to the T cell 
medium in order to provide stimuli for memory T cell maintenance and survival (Barker 
et al., 2010; Brincks and Woodland, 2010; Cha et al., 2010; Knutson and Disis, 2001; 
Schluns et al., 2000; Weng et al., 2002). It has been demonstrated that the transfer of 
memory T cells may mediate a strong an anti-tumor response (Klebanoff et al., 2005). 
However, after 40 h of coculture the relative amount of CD8+ TEM and CD8+ TCM cells 
decreased. This phenomenon has also been observed with tumor infiltrating lymphocytes 
from melanoma patients using the rapid expansion protocol (REP) for T cell expansion 
(Dudley et al., 2003; Zhou et al., 2011). Furthermore, the relative amount of TRP-2-
specific T cells did not increase but rather decrease during the culture. An ex vivo 
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expansion of tumor-specific T cells is not always feasible due to the low frequency of 
those cells (Fig.13; 3.1% ± 1.7% on day 0), resulting in loss of homing receptor, i.e. 
CD62L, and downregulation of CD44 (Zhou et al., 2011). An optimal memory T cell 
expansion could for instance be achieved with the recently published culture protocol for 
specific in vitro expansion of highly purified naïve CD8+ T cells using peptide-pulsed DC 
in combination with sequential supplement of IL-21, IL-7 and IL-15. An expansion of 
approximately 200-fold of the initial antigen-specific population was achieved, and the 
anti-tumor reactive T cells showed a TCM-like phenotype expressing CD62L (Wolfl et al., 
2011).  
The early activation marker CD69 is one of the earliest cell surface antigens expressed by 
T cells following their activation (Ziegler et al., 1994). The CD69 expression on freshly 
isolated T cells was around 14.0%, and after the stimulation with tumor lysate pulsed 
DC, it increased up to 36.1%. We also measured the PD-1 expression on T cells which is 
linked to T cell exhaustion and is expressed on activated T cells (Freeman et al., 2000). 
However, the relative amount of PD-1 expressing cells did not increase after T cell 
stimulation with DC. 
Since the TRP-2-specificity and the activation status of CD8+ T cells was the highest 
after 40 h of coculture, we decided to use the cells for adoptive transfer at this time 
point.  
 
5.3 Migration properties and phenotype of transferred T 
cells  
Since the T cells after coculture were active and exhibited TRP-2 specificity we 
determined their migration after an adoptive transfer into ret transgenic tumor-bearing 
mice. To achieve an effective adoptive immunotherapy, T cells, which are transferred, 
should have the ability to migrate to the tumor site. As it has been previously shown, ex 
vivo expanded and adoptively transferred T cells from melanoma patients persist in vivo 
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and preferentially localize to tumor sites (Yee et al., 2002). They mediate an antigen-
specific immune response characterized by, e.g. elimination of antigen-positive tumor 
cells and regression of metastases. In another study, transferred autologous, re-activated 
BM memory T cells were transferred together with DC into NOD/SCID mice harboring 
xenotransplanted human breast tumors (Beckhove et al., 2004). A co-localization CD4+ 
and CD8+ with DC was detected in the tumor transplants. Therefore, we transferred 
both T cells and DC, after 40 h of their co-culture into tumor-bearing mice. In the 
beginning of this study, an adoptive transfer was performed via i.p. injections since ret 
transgenic mice have hyperpigmented, dark tails, and the tail veins are difficult to reach. 
Very low numbers of injected T cells were able to migrate into tumor lesions at day 3, 5 
and 7. At day 7 after the transfer, CPD-labeled T cells could be detected also in 
metastatic lymph nodes. We found a relatively high amount of CPD+ cells in the 
peritoneal cavity. One reason could be that the concentration of chemokines responsible 
for T cell homing into the periphery was not enough, and the transferred T cells 
remained in the peritoneum. In addition, the amount of transferred cells was only 1.2-
2.0x106 per mouse due to the low yield of T cells from the BM. In former publications, 
the amount of transferred T cells was at least 4x106 per mouse (Beckhove et al., 2004; 
Feuerer et al., 2001a; Umansky et al., 2008).  
In further experiments we performed intracardiac injections of in vitro re-activated T 
cells and DC to avoid the persistence of transferred T cells in the peritoneal cavity. 
Adoptively transferred CPD-labeled cells were capable to migrate into tumor lesions. 
Furthermore, these cells could home to the BM and the secondary lymphoid organs such 
as spleen and metastatic lymph nodes. When we transferred in vitro activated CFSE-
labeled TRP-2 TCR transgenic activated T cells, we observed a similar migration 
pattern of labeled cells. After the calculation of absolute numbers of migrated cells in 
respected organs and tumor lesions, we found that at day 3 after adoptive transfer, 
highest amounts of CPD+ cells were detected in metastatic lymph nodes followed by 
spleen and the BM. In the tumor, the number of cells reached 1x106 cells, whereas in the 
BM it was 3x106, in the spleen -1.5x107 and in metastatic lymph nodes -3.5x107. 
Therefore, the number of detected cells was higher than initially injected (~3x106 
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cells/mouse) indicating their proliferation in vivo. Later, the absolute amount of 
migrated cells significantly increased in the tumor, by contrast in spleen, the cell number 
did not change and in the lymph nodes they even decreased. In the BM, the absolute 
amount of tracked cells slightly increased at day 7. Since the BM was shown to be a 
preferential site for the migration and selective retention of memory T cells and DC 
(Feuerer et al., 2001a; Feuerer et al., 2001b), it is not surprising that adoptively 
transferred cells migrate into the BM.  
It is feasible that migrated cells may proliferate in the BM, lymph nodes and the spleen 
and then migrate to the tumor site. It has been reported that in the BM, T cells are 
condensed in lymphoid follicles surrounding a blood vessel and the frequency of such 
follicles can be increased during infections, inflammation and autoimmunity (Bain, 2001; 
Custer, 1973). Moreover, BM can serve as a secondary lymphatic organ and it appears to 
be important for systemic T cell-mediated immune response as demonstrated earlier 
(Feuerer et al., 2003). Furthermore, T cells are homing to the BM and form multicellular 
clusters together with resident CD11c+ DC, which can take up blood-borne antigen and 
serve as APCs for naïve or memory T cells (Schirrmacher et al., 2003). As a result, 
interactions between BM derived-DC and antigen-specific T cells lead to the 
upregulation of CD69 on T cells and their subsequent clonal expansion (Schirrmacher et 
al., 2003).  
Next, we took a closer look at the phenotype of T cells migrated into the tumor. We 
found that at day 3 after adoptive transfer, there was no significant difference between 
effector, central memory and naive CD8+ T cells. The number of TEM cells was lower 
than that of the other CD8+ T cell subsets. However, at day 5 and 7 post injection, the 
relative amount of effector memory CD8+ T cells increased whereas the numbers of naive 
and central memory T cells significantly decreased. A significant increase of effector 
CD8+ T cells was found in the tumor at day 7 after i.c. injection. Our findings are 
similar to the data reported earlier (Pages et al., 2005).  Presence of high levels of 
infiltrating memory and effector CD8+ T cells was found in patients after examining 
local immune response within the tumor specimens of resected colorectal cancer (Pages 
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et al., 2005). Recently, Thompson et al. (2010) reported T cell infiltration into the tumor 
after an adoptive transfer of naïve T cells in B16 melanoma. OT-I T cells, which were 
found within the tumors, expressed effector functions. 
When we used stimulated TRP-2 TCR transgenic effector T cells for an adoptive 
transfer, we could detect similar migration properties as in adoptive transfer of T cells 
from the BM of ret tg mice. T cells were trafficking into secondary lymph nodes as well 
as into BM of ret transgenic tumor-bearing mice. Furthermore, we have observed a 
continuous accumulation of CFSE+ cells within the tumor. Here, we used 1x107 T 
cells/mouse, it is 5 times more than we used in the experiment with BM derived T cells, 
but we observed a four times lower absolute amount of labeled T cells migrated into the 
spleen. On the contrary, more infiltrating T cells were found at day 7 in the tumor 
compared to the previous experimental setup with restimulated memory T cells 
(22.6±18.9x105 cells vs. 7.2±3.2x105 cells). This can be due to the fact that these TRP-2 
TCR transgenic T cells displayed CD8+ effector T cell phenotype. It is known that once 
the antigen-specific effector T cells are activated they migrate through the endothelial 
cell wall to inflamed tissues or tumor sites where they exert their effector function by 
releasing cytotoxins such as perforin, granzymes and granulysin (Barry and Bleackley, 
2002). Since effector T cells have a decreased expression of homing receptors like L-
selectin (CD62L) and CC-chemokine receptor 7 (CCR7), they have a reduced potential 
for homing to secondary lymphoid organs (Finlay and Cantrell, 2011). However, with the 
increased expression of chemokine receptors CCR5 and CCR2 they have a greater 
capacity to migrate to inflamed tissues (Kaech et al., 2002). It is therefore reasonable 
that in our experiment with the adoptive transfer of TRP-2 TCR transgenic CD8+ 
effector T cells we detected less CFSE+ cells in the spleen and a greater absolute amount 
in the tumor compared to the adoptive transfer of restimulated memory T cells and DC. 
We found equal amounts of naive, effector, TCM and TEM CD8+ TRP-2 TCR transgenic T 
cells at day 3 and 5. On day 7, we measured a slightly decreased relative amount of Teff 
and Tnaive CD8+ cells but an increase in effector memory CD8+ T cell numbers. In 
contrast, the relative amount of Teff CD8+ cells increased when using activated BM-
derived T cells from ret transgenic mice. 
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We hypothesize that transferred T cells migrate to secondary lymphoid organs, the BM 
and only a small number does migrate into tumor lesions. They are activated by APCs, 
clonally expanded and change their phenotype. Thereafter, effector T cells migrate into 
tumor lesions and exert their effector functions.  
 
5.4 Melanoma-specific reactivity in vivo of in vitro 
activated T cells  
We have shown that restimulated BM derived T cells from ret transgenic mice with and 
without visible tumors are capable to migrate into metastatic lymph nodes and to tumor 
sites. Furthermore, these cells migrate to spleen and the BM, where they encounter 
antigens presented by APCs and are clonally expanded. In our next experiments, we 
examined the anti-tumor activity of adoptively transferred BM-derived T cells from ret 
transgenic mice after 40 h of restimulation with DC pulsed with tumor lysate. The 
therapy with melanoma-antigen specific cells leads to a significant increase of the overall 
survival of tumor-bearing mice compared to mice treated with PBS. Although the 
tumors did not disappear, the tumor growth was significantly delayed. Moreover, mice in 
the treated group appeared more active and their fur was shiny compared with the 
untreated group where mice were moving very slow, had a sickly appearance and their 
fur was dull.  
It has been recently reported that after the manipulation of the tumor microenvironment 
with PDE-5 inhibitor sildenafil, the amounts of MDSCs and their inhibitory functions 
were decreased (Meyer et al., 2011). Furthermore, a reduction of inflammatory mediators 
such as IL-6, IL-1ß, VEGF and S100A9 was observed which led to a partial restoration 
of the ζ-chain expression on T cells and a significantly increased survival. Therefore, we 
decided to treat tumor-bearing mice with sildenafil one week before the adoptive 
transfer. The survival of mice pretreated with sildenafil and AT of reactivated BM-
derived T cells was significantly increased compared to the PBS group and the group 
treated with sildenafil alone. Since the amount of animals per group was low due to the 
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humble numbers of T cells in the murine BM, experiments have to be repeated to 
confirm these results.  
When we used in vitro generated TRP-2-specific effector T cells from TRP-2 TCR 
transgenic mice for therapy, we were not able to observe the same effects as after the 
therapy with memory T cells even in the combination with sildenafil. Although TRP-2-
specific T cells were found to migrate into tumor lesions, they might be inhibited by the 
immunosuppressive cells and mediators of the tumor microenvironment. Once the T cells 
are inhibited, they either undergo apoptosis or remain in an anergic state (Dong et al., 
2002; Selenko-Gebauer et al., 2003).  
 
BM-derived reactivated memory T cells from ret transgenic mice could be a promising 
tool for adoptive immunotherapy against melanoma since they are capable to migrate 
into tumor lesions and lymphatic organs. Their differentiation from TCM into TEM and Teff 
cells within the tumor is implicated by the increase and decrease of the respective T cell 
subsets over time. Moreover, their anti-tumor reactivity could be determined by a 
significantly prolonged survival in tumor-bearing mice after adoptive transfer of these 
cells alone and in combination with the inhibition of the MDSC-induced 
immunosuppression. 
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